bims-carter Biomed News
on CAR-T Therapies
Issue of 2026–11–01
76 papers selected by
Luca Bolliger, lxBio



  1. Crit Rev Oncog. 2026 ;31(2): 55-64
      Chimeric antigen receptor (CAR) T cell therapy has transformed cancer immunotherapy. Still, conventional viral vectors carry risks of insertional mutagenesis, are costly to manufacture, and can cause persistent on-target/off-tumor toxicity. Messenger RNA (mRNA) platforms offer a nonintegrating, transient alternative that enables rapid, modular expression of CARs and accessory molecules and can be extensively optimized. mRNA CAR T cells can be manufactured in days, and their transient expression allows repeat dosing and mitigates prolonged toxicity. Preclinical studies show that electroporation or lipid nanoparticle delivery can generate potent CAR-engineered immune cells. Beyond oncology, transient mRNA CARs are explored for autoimmune diseases such as systemic lupus erythematosus, lupus nephritis and myasthenia gravis, where short-lived CAR expression can reset autoreactive B-cell compartments while avoiding long-term immunosuppression. Emerging delivery strategies, including targeted lipid nanoparticles that program T cells in vivo, could eliminate the need for ex vivo cell manufacture and extend CAR therapy to fibrosis and regenerative medicine. Collectively, these developments position mRNA-engineered CARs as a flexible, safer and scalable platform that complements or potentially surpasses viral CAR technologies in oncology, autoimmunity and beyond.
    DOI:  https://doi.org/10.1615/CritRevOncog.2026066109
  2. Crit Rev Oncog. 2026 ;31(2): 35-46
      Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of refractory haematological malignancies, yet its success remains limited by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Although earlier intervention with tocilizumab and corticosteroids has reduced the incidence of severe toxicity, these strategies act after inflammatory signaling is already established and do not reliably prevent isolated or delayed neurological complications. This has shifted the field from reactive management towards prevention at the level of the cellular product itself. Manufacturing conditions, cellular compositions and differentiation state can shape the inflammatory setpoint of CAR T cells, but attempts to preserve less-differentiated, highly proliferative populations may also increase expansion-driven toxicity. Construct engineering therefore aims not simply to weaken CAR activity, but to recalibrate antigen recognition, signaling strength and cytokine output while preserving durable tumor control. Multimodal reversible CAR engineering approaches via drug-gated receptors, safety switches, transient surface shielding, and targeted CAR degradation, further recast CAR T cells as tuneable therapeutic systems rather than fixed products. However, most evidence remains preclinical or derived from small, heterogeneous studies. Progress will depend on prospective trials that evaluate efficacy and neurotoxicity together, using harmonised product analytics, neurological endpoints and longitudinal biomarker sampling to define clinically meaningful safety/activity trade-offs.
    DOI:  https://doi.org/10.1615/CritRevOncog.2026066328
  3. Front Immunol. 2026 ;17 1897153
       Background: Chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) have transformed treatment for relapsed/refractory multiple myeloma (RRMM). Contemporary guidelines increasingly incorporate prior antigen-directed exposure, disease kinetics, patient fitness, toxicity, access, and patient preference. However, a prospectively validated framework that jointly operationalizes immune fitness, tumor antigen status, and treatment feasibility for sequencing T-cell-redirecting therapies is not available.
    Main body: This Perspective introduces the Adaptive Immunotherapy Sequencing Model (AISM), an author-proposed framework for research and multidisciplinary discussion. AISM proposes that sequencing should be studied in relation to two evolving biological domains: the capacity of the host T-cell compartment to support therapy and the probability that the relevant tumor antigen remains therapeutically actionable. The model uses provisional 0-10 research constructs for T-cell fitness and antigen-escape risk to make these domains explicit. AISM hypothesizes that, for eligible patients with early RRMM and feasible access, referral for BCMA-directed CAR-T before prolonged exposure to T-cell-redirecting BsAbs may preserve a potentially favorable treatment option. It also recognizes that off-the-shelf BsAbs may be necessary when disease tempo, frailty, access, or patient preference make CAR-T impracticable. After prior BCMA-directed therapy, an antigen-switching approach is biologically plausible, but antigen loss is not universal and other mechanisms of resistance must be considered.
    Conclusions: AISM provides a testable framework for prospective comparative studies. Such studies should evaluate whether biologically informed sequencing improves progression-free survival (PFS), while also assessing overall survival, toxicity, infections, treatment-free time, feasibility, and patient-reported outcomes.
    Keywords:  CAR-T cell therapy; T-cell fitness; adaptive immunotherapy sequencing model; antigen escape; bispecific antibodies; multiple myeloma; relapsed/refractory
    DOI:  https://doi.org/10.3389/fimmu.2026.1897153
  4. Rinsho Ketsueki. 2026 ;67(9): 1376-1382
      Chimeric antigen receptor T (CAR-T) cell therapy, originally established for hematologic malignancies, has recently attracted attention as a novel therapeutic strategy for systemic autoimmune rheumatic diseases. By targeting CD19, CAR-T cells induce broad depletion of autoreactive B cells, leading to immune reconstitution. In systemic autoimmune rheumatic diseases, B cells play a central role not only in autoantibody production but also in antigen presentation and cytokine-mediated immune responses. Therefore, comprehensive elimination of B cells is considered an effective approach for disease control. Early clinical studies have demonstrated high remission rates in refractory cases, including systemic lupus erythematosus, with some patients achieving drug-free remission, suggesting deeper disease control beyond that attainable with conventional therapies. In terms of safety, cytokine release syndrome and neurotoxicity are generally milder than those observed in hematologic malignancies. In addition, a characteristic toxicity known as local immune effector cell-associated toxicity syndrome (LICATS) has been reported, presenting as transient inflammation localized to previously affected organs. Future challenges include optimizing CAR-T cell design with an emphasis on safety and controllability, as well as determining the optimal timing of treatment. CAR-T cell therapy holds curative potential and may redefine the treatment paradigm for systemic autoimmune rheumatic diseases.
    Keywords:  B-cell depletion; CAR-T cell therapy; Immune reset; Systemic autoimmune rheumatic diseases
    DOI:  https://doi.org/10.11406/rinketsu.67.1376
  5. Med J Aust. 2026 Nov;pii: e70321. [Epub ahead of print]224(11):
      Adoptive cellular therapies (ACT), including tumour-infiltrating lymphocyte (TIL), T-cell receptor-engineered T (TCR-T) cell and chimeric antigen receptor T-cell (CAR-T) therapies, represent an evolving class of immunotherapies with established efficacy in selected haematological malignancies and emerging applications in solid tumours. Additional platforms under investigation include virus-specific T cells, tumour-associated antigen-specific T cells, natural killer (NK) cell therapies and dendritic cell-based therapies. The therapeutic scope of ACT is expanding beyond oncology into autoimmune and fibrotic diseases, infectious diseases and inherited metabolic and immune disorders, highlighting the broad potential of cellular immunotherapy platforms. In solid tumours, efficacy remains limited by tumour antigen heterogeneity, immunosuppressive tumour micro-environment and impaired immune cell trafficking and persistence. These barriers are driving development of next-generation cellular products and combination strategies. Characteristic immune-mediated toxicities, particularly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), remain important considerations. Although potentially severe, these toxicities are generally manageable with early recognition, multidisciplinary care and prompt specialist intervention. As ACT indications expand in Australia, clinician familiarity with indications, mechanisms of action and toxicity profiles is essential to support informed patient discussions, appropriate patient selection, timely referral and prompt toxicity recognition and management. Non-oncology specialists have an important role in shared care, including patient identification, referral coordination, monitoring for delayed or late toxicities and provision of ongoing survivorship and supportive care. Achieving equitable national access to ACT will require streamlined health technology assessment processes, coordinated reimbursement and delivery funding models and structured referral networks with cross-institutional collaboration to support the specialised infrastructure required for their delivery.
    Keywords:  adoptive cellular therapy; healthcare access; solid tumours; toxicities
    DOI:  https://doi.org/10.5694/mja2.70321
  6. Front Immunol. 2026 ;17 1968080
      Chimeric Antigen Receptor T (CAR-T) cell therapy has emerged as a promising therapeutic option, particularly for refractory and relapsed leukemias. However, its efficacy in treating solid tumors, including lung, ovarian, gastric, and breast cancers, remains limited by several challenges. Recent studies have highlighted CAR-T cell immunotherapy as a potential treatment for these malignancies, utilizing genetically engineered T cells that target specific tumor antigens. For successful therapy, it is crucial to identify antigens that are selectively expressed on tumor cells but not on normal tissues. In lung cancer, however, the lack of specific tumor-associated antigens, the immunosuppressive tumor microenvironment, limited CAR-T cell infiltration, and off-target effects complicate the development of effective CAR-T therapies. This review outlines the fundamental structure and generation of CAR-T cells, summarizes key tumor-associated antigens targeted in clinical trials for these cancers, and discusses the current challenges and emerging strategies. The goal is to provide insights and potential approaches to enhance the design and execution of preclinical and clinical CAR-T cell therapies for these solid tumors.
    Keywords:  car-t; immunotherapy; solid tumors; therapeutic strategies; tumor antigens
    DOI:  https://doi.org/10.3389/fimmu.2026.1968080
  7. Med Sci Monit. 2026 Oct 26. 32 e953538
      Chimeric antigen receptor T-cell (CAR-T) therapy represents a transformative breakthrough in the treatment of hematological malignancies. However, its clinical efficacy against solid tumors is greatly hindered by physical stromal barriers and a complex, immunosuppressive tumor microenvironment (TME). In addition to these biological hurdles, the high cost of ex vivo manufacturing and the risk of severe adverse effects, such as cytokine release syndrome, limit widespread patient access. The aim of this review was to analyze reports published between 2020 and 2025 regarding the use of viral and synthetic nanoplatforms to improve the safety and efficacy of CAR-T therapy, with a particular focus on ex vivo cell engineering and innovative strategies for in vivo CAR-T cell generation. The review first evaluates how lipid- and polymer-based nanoparticles, acting as nonviral vectors, can revolutionize CAR-T engineering by providing cost-effective alternatives to viral transduction, accelerating cell preparation, and minimizing the risks associated with random genomic integration. It then examines the application of multifunctional nanocatalysts designed to enhance T-cell infiltration and actively modulate the TME to overcome immune evasion. Crucially, the review explores cutting-edge in vivo platforms, including VivoVec and adaptable chimeric antigen receptor T-cell (AdCAR-T) systems, which facilitate direct endogenous lymphocyte reprogramming, thus bypassing lymphodepletion and the logistical burdens of specialized laboratory processing. Integration of these nanotechnologies into such workflows enables the development of "smart," controllable therapeutic systems that improve both safety and scalability in personalized oncology.
    DOI:  https://doi.org/10.12659/MSM.953538
  8. ACS Bio Med Chem Au. 2026 Oct 21. 6(5): 579-593
      Chimeric antigen receptor (CAR) T-cell therapies have fundamentally reshaped clinical oncology by achieving durable remissions in refractory hematologic malignancies. However, their broader translation remains bottlenecked by severe, treatment-associated hyperinflammatory toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Current management strategies are reactive and rely on systemic immunosuppressants, such as corticosteroids and the anti-IL-6 receptor antibody tocilizumab. While these interventions blunt acute inflammation, they can exert systemic effects that have the possibility to impair CAR-T cell persistence, prolong cytopenias, and compromise long-term antitumor efficacy. In this review, we challenge the conventional paradigm that treats toxicity as a uniform, unavoidable consequence of systemic immune activation. Instead, we present emerging evidence demonstrating that CAR-T-associated toxicities possess discrete spatial, temporal, and kinetic organization across distinct tissue compartments and biological phases. We propose a cohesive engineering framework that leverages advanced drug delivery technologies to convert toxicity management from a reactive clinical hurdle into a systems-level design problem. By organizing future therapeutic strategies around three core pillars: temporal control (gating interventions to specific phases of immune escalation), dosing and kinetic control (flattening proliferation slopes via fractionated delivery, dynamic feedback loops, and mathematical modeling), and spatial control (anatomical targeting of inflamed vasculature, lymphoid organs, and the central nervous system), it may be possible to selectively decouple localized toxic inflammatory cascades from therapeutic CAR-T cell expansion. Ultimately, integrating these spatiotemporal and kinetic parameters provides a blueprint for engineering the next generation of safer, scalable, and highly efficacious cellular immunotherapies.
    Keywords:  cellular immunotherapy; chimeric antigen receptor (CAR) T-cell; cytokine release syndrome (CRS); cytokine signaling; drug delivery; hemophagocytic lymphohistocytosis (HLH); immune modulation; immunotoxicity; neurotoxicity; toxicity
    DOI:  https://doi.org/10.1021/acsbiomedchemau.6c00127
  9. Crit Rev Oncog. 2026 ;31(2): 3-21
      T cell functions are tightly regulated by signaling through the MHC-restricted T cell antigen receptor (TCR), a multi-chain complex that synergizes with CD28 and other costimulatory receptors. Beginning in the late 1980s, simplified chimeric constructs illuminated core mechanisms of TCR signaling, while setting the stage for the development of chimeric antigen receptor (CAR) T cell therapies. Composed of a single transmembrane chain, US Food and Drug Administration (FDA)-approved, second-generation CARs link an antibody-based recognition moiety to intracellular costimulatory and CD3 ζ signaling motifs. CARs harness key aspects of T cell mediated immunity while bypassing MHC-restriction; yet these single-chain constructs do not recapitulate the extraordinary antigen sensitivity of the native TCR. Emerging evidence attributes this deficit, in part, to impaired CAR coupling to the LAT-SLP-76 signalosome, a multi-protein complex downstream of ZAP-70, that integrates TCR proximal signals and drives PLC-γ1-dependent cellular responses. Recent studies describe innovative strategies to increase CAR T sensitivity, potency and specificity, by replacing or supplementing conventional CARs with LAT or SLP-76-based constructs that enhance signalosome engagement and promote ITK- and PLC-γ1-mediated signaling. These advances chart a path toward more effective CAR T therapies, while illuminating the mechanisms by which LAT and SLP-76 govern antigen sensitivity.
    DOI:  https://doi.org/10.1615/CritRevOncog.2026065228
  10. Med Rev (2021). 2026 Oct;6(5): 379-401
      Chimeric antigen receptor (CAR) T cells have revolutionized oncology, delivering unprecedented clinical responses in patients with refractory B-cell malignancies. However, the traditional autologous paradigm - encompassing patient-specific leukapheresis, genetic modification, and extensive ex vivo expansion - imposes severe constraints on manufacturing timelines, costs, and global scalability. Allogeneic universal CAR-T (uCAR-T) reimagines this therapeutic unit as an "off-the-shelf" cellular medicine, utilizing healthy donor-derived cells produced in standardized batches to overcome the bottlenecks of individualized therapy. Over the past decade, the field has transitioned from foundational proof-of-concept studies in murine models to sophisticated early-phase human clinical trials. This review delineates the core biological and engineering principles of uCAR-T, specifically focusing on the genomic strategies employed to mitigate graft-versus-host disease (GvHD) and host-versus-graft disease (HvGD). We synthesize pivotal preclinical and clinical data alongside a comprehensive overview of the current clinical landscape. Furthermore, we highlight the primary translational hurdles remaining: ensuring durable CAR-T persistence and navigating the complexities of innate and adaptive immune rejection. We explore the potential for combination immunotherapies and specialized CAR architectures designed to penetrate solid tumors. Ultimately, uCAR-T is poised to democratize cellular immunotherapy, offering a scalable and transformative therapeutic perspective across diverse disease indications.
    Keywords:  GvHD; HvGD; cancer immunotherapy; cell therapy; universal CAR-T
    DOI:  https://doi.org/10.1515/mr-2026-0017
  11. Front Immunol. 2026 ;17 1939919
      Tumor antigens provide the molecular interface between malignant transformation and host immunity, but their biological significance is determined by more than their molecular existence. Antigen clonality, abundance, processing, human leukocyte antigen (HLA) presentation, dendritic-cell function, T-cell recognition, spatial immune organization, and the surrounding tumor microenvironment (TME) collectively determine whether an antigen becomes immunologically visible and therapeutically actionable. Across cancer progression, tumor-cell antigenic states and the TME undergo reciprocal selection: immune pressure can eliminate highly visible clones while favoring antigen-loss variants, HLA defects, immune exclusion, suppressive myeloid and stromal states, and treatment-resistant populations. Recent single-cell, spatial and three-dimensional imaging, as well as immunopeptidomic studies show that this evolution is heterogeneous across tumor regions and anatomical compartments rather than a uniform linear process. This review therefore advances an antigen-TME co-evolution framework linking primary tumors, lymphatic and nodal immune compartments, systemic dissemination, distant metastatic niches, therapy, minimal residual disease, and recurrence. It critically evaluates the strengths and limitations of the classical immunoediting model; compares melanoma, breast, colorectal, lung, prostate, sarcoma, and virus-associated cancers according to antigen source, clonality, presentation competence, immune architecture, and dominant therapeutic bottleneck; and examines clinical translation through checkpoint blockade, cellular therapy, vaccines, antibodies, antibody-drug conjugates, immunopeptidomics, and computational antigen prediction. Particular attention is given to the gap between predicted peptide binding and verified presentation or immunogenicity, the need for longitudinal rather than single-biopsy profiling, and the requirement for prospective validation of artificial-intelligence models. The central conclusion is that tumor antigens become clinically meaningful only when antigenic state and microenvironmental context are assessed together, providing a more rigorous foundation for precision cancer immunotherapy.
    Keywords:  antigen presentation; cancer immunoediting; immune escape; immunopeptidomics; precision cancer therapy; spatial biology; tumor antigens; tumor microenvironment
    DOI:  https://doi.org/10.3389/fimmu.2026.1939919
  12. Front Immunol. 2026 ;17 1942249
      Autoimmune neurologic diseases include multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, autoimmune encephalitis, myasthenia gravis, stiff-person syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and related syndromes. The contributions of B cells, plasma cells, and autoantibodies differ substantially across these disorders; however, the B-cell lineage represents a therapeutically actionable target in many of them. Chimeric antigen receptor T-cell therapy, originally developed for hematologic malignancies, offers a potential strategy for deep and potentially durable depletion of pathogenic B-lineage cells and subsequent immune reconstitution. In recent years, CD19, BCMA, dual-target, mRNA CAR-T-cell, and chimeric autoantibody receptor T-cell approaches have generated preliminary clinical or translational evidence, primarily in systemic autoimmune diseases. Clinical evidence in neurologic disorders remains limited and spans myasthenia gravis, NMOSD, MOGAD, multiple sclerosis, autoimmune encephalitis, stiff-person syndrome, and CIDP. This review summarizes the biologic rationale, disease-specific evidence, target selection, safety concerns, and trial-design considerations for CAR-T-cell therapy in autoimmune neurologic diseases. Current evidence supports further investigation of CAR-T cells in selected patients with highly refractory, antibody- or B-cell-driven neuroimmune disorders, but does not establish superiority over existing therapies. However, the field remains dominated by case reports and small early-phase studies, with randomized evidence currently confined to one phase 2b trial in myasthenia gravis. Establishing the risk-benefit profile will require stringent patient selection, disease-specific neurologic monitoring, controlled prospective studies, and long-term follow-up.
    Keywords:  B cells; BCMA; CAR-T cells; MOGAD; autoimmune neurologic disease; multiple sclerosis; myasthenia gravis; neuroimmunology
    DOI:  https://doi.org/10.3389/fimmu.2026.1942249
  13. Front Genome Ed. 2026 ;8 1943068
      Chimeric antigen receptor (CAR)-based immunotherapy has transformed cancer treatment by enabling engineered immune cells to selectively recognize and eliminate malignant targets, with CAR-T cells establishing the first major clinical success in this field. However, severe associated toxicities, logistical complexities of autologous manufacturing, and high rates of antigen-loss relapse have accelerated the development of alternative effector platforms such as CAR-NK cells. CAR-NK cells combine antigen-directed cytotoxicity with the innate antitumor functions of natural killer cells, offering a potentially safer and more readily available off-the-shelf therapeutic strategy. Nevertheless, the clinical efficacy of CAR-NK therapy is constrained by key biological and translational hurdles: brief in vivo persistence, inadequate trafficking and solid tumor infiltration, severe susceptibility to tumor microenvironment-mediated immunosuppression, and antigen escape driven by tumor heterogeneity. These biological constraints are compounded by technical bottlenecks, including cell source variability, limited large-scale expansion capacity, ex vivo functional exhaustion, and an absence of standardized manufacturing protocols. To address these multi-faceted barriers, recent advances in genome engineering, systems biology, and computational modeling provide promising routes forward. Given that prolonged exposure to immunosuppressive niches induces functional impairment, genome-editing strategies targeting inhibitory checkpoints and persistence programs are crucial; however, enhancing persistence requires stringent safeguards to mitigate toxicity risks from constitutive signaling or genomic instability. Thus, engineering next-generation CAR-NK cells necessitates balancing extended longevity, potent cytotoxicity, and safety. Multiomics approaches facilitate deeper characterization of CAR-NK functional states and tumor-immune interactions, whereas artificial intelligence-guided engineering integrates high-dimensional biological and manufacturing data to optimize receptor design, predict therapeutic performance, and accelerate translational workflows. Collectively, these innovations support a paradigm shift toward programmable CAR-NK cells that can dynamically sense, adapt, and respond to tumor evolution, driving the transition toward autonomous, highly scalable, and precisely controllable cellular immunotherapies in precision oncology.
    Keywords:  CAR-NK cells; CAR-based immunotherapy; CRISPR genome editing; cancer immunotherapy; synthetic biology
    DOI:  https://doi.org/10.3389/fgeed.2026.1943068
  14. Front Med (Lausanne). 2026 ;13 1987146
      Osteosarcoma remains a therapeutically difficult malignancy, particularly after metastatic relapse, and immune checkpoint blockade or adoptive cell therapy has not reproduced the durable responses achieved in more immunogenic cancers. The central translational problem is not a complete absence of immune activity, but marked interpatient, intratumoral, and spatial heterogeneity in immune access, antigen presentation, myeloid suppression, stromal exclusion, and target-antigen expression. This Mini Review synthesizes recent single-cell and spatial profiling studies with tissue, circulating, and clinical biomarker evidence to define a practical framework for biomarker-guided immunotherapy. Osteosarcoma ecosystems can contain lymphoid-excluded, myeloid-dominant, angiogenic-hypoxic, checkpoint-rich, and antigen-high states that may coexist within the same patient. Consequently, programmed death-ligand 1 (PD-L1) alone is unlikely to function as a reliable treatment-selection marker. A composite assessment integrating human leukocyte antigen (HLA) class I and antigen-processing competence, CD8/regulatory T-cell topology, macrophage and myeloid-derived suppressor cell programs, vascular and extracellular-matrix barriers, and quantitative surface-antigen density is more biologically defensible. Dynamic measurements, including circulating tumor DNA, soluble B7-H3, exosomal immune signals, and serial imaging, may complement tissue profiling but remain investigational. Clinical experience with checkpoint inhibitors, antiangiogenic combinations, mifamurtide, HER2-directed approaches, and emerging B7-H3-, GD2-, ALPL-1-, CD166-, IL-11Ralpha-, and NKG2D-based cellular therapies underscores the need to match mechanism to phenotype. Prospective studies should therefore use standardized, spatially resolved, and longitudinal biomarker panels to enrich trials, distinguish prognostic from predictive effects, and adapt therapy when immune exclusion or antigen escape emerges.
    Keywords:  CAR T cells; biomarkers; circulating tumor DNA; immune checkpoint blockade; immunotherapy; osteosarcoma; patient stratification; tumor immune microenvironment
    DOI:  https://doi.org/10.3389/fmed.2026.1987146
  15. Exploration (Beijing). 2026 Oct 21. 70230
      Chimeric antigen receptor (CAR)-T cell therapy has emerged as a groundbreaking treatment for cancer. After decades of research, it is now being actively explored for a broader range of immune-mediated diseases, particularly cancer and autoimmune disorders. Significant progress has been made in both understanding technological advancements and addressing the intrinsic limitations of this engineered cellular therapy. However, the clinical efficacy and safety of CAR-T cells remain influenced by several factors, including the immunosuppressive tumour microenvironment (TME), the continuous mutational evolution of tumour cells, the prohibitive cost of production limiting accessibility, and the immune-related toxicities associated with biologic treatments. Given these substantial challenges, a paradigm shift is urgently needed - from conceptualizing CAR-T cells solely as "engineered immune cells" to recognizing them as "programmable intelligent systems." This review proposes a dynamic immune engineering framework, advocating that the next generation of CAR-T cells be conceived as programmable immune systems capable of sensing, responding to, and self-regulating immune responses. This evolving approach positions dynamic immune regulation as the core principle underlying immune system function. Ultimately, this review aims to provide a conceptual and theoretical foundation for the development of next-generation CAR-T therapies that are not only highly effective but also cost-efficient and globally accessible.
    Keywords:  CAR‐T cell therapy; autoimmune disorders; cancer; dynamic immune engineering
    DOI:  https://doi.org/10.1002/exp2.70230
  16. Rinsho Ketsueki. 2026 ;67(9): 1383-1391
      Natural killer (NK) cells are cytotoxic lymphocytes that play an essential role in controlling viral infections and cancer. Although tumor cells and virus-infected cells with reduced expression of major histocompatibility complex (MHC) class I molecules can escape from T cell-mediated immune responses, NK cells use a variety of receptors to recognize and efficiently eradicate these targets through cytotoxic activity. NK cells are also an attractive tool for the development of therapies for incurable viral infections and cancer. However, effective strategies to enhance NK cell-mediated immune responses have not yet been established. This article provides an overview of the mechanisms underlying target recognition by NK cells. It also explains the adaptive immune features, including antigen-specific proliferation and differentiation into memory NK cells, as an emerging aspect of NK cell biology. Furthermore, it outlines chimeric antigen receptor (CAR) NK cell therapy as a therapeutic approach for invigorating the anti-tumor activity of NK cells, and reviews recent research trends, including the current status and challenges of CAR-NK cells.
    Keywords:  Adaptive immune features; CAR-NK cells; NK receptors; Natural killer cells
    DOI:  https://doi.org/10.11406/rinketsu.67.1383
  17. J Control Release. 2026 Oct 30. pii: S0168-3659(26)00915-6. [Epub ahead of print] 115511
      Conventional ex vivo chimeric antigen receptor (CAR) T cell therapy is limited by cumbersome manufacturing workflows, prohibitive costs and various treatment-related risks. In vivo CAR-T technology directly generates engineered cells within patients, conferring distinct advantages in operational simplicity, biosafety and clinical accessibility. This review systematically evaluates existing delivery platforms and classifies in vivo CAR-T into two core paradigms: persistent engineering and transient reprogramming, each featuring distinct properties tailored to different clinical indications. It further summarizes preclinical advances and clinical data covering hematological malignancies, solid tumors, autoimmune disorders and organ fibrosis, in which numerous investigational candidates have exhibited encouraging efficacy. Ultimately, five translational barriers summarized as the 5S challenges (specificity, stability, safety, suppression and scalability) and their matched optimization tactics are comprehensively discussed. This review provides a clinician-oriented decision matrix that links carriers selection to disease biology, and a 5S optimization framework to guide next-generation vector design. Collectively, these insights establish a translational roadmap for customizing in vivo CAR-T design to specific clinical indications and take a critical step toward realizing the full therapeutic potential of this disruptive modality.
    Keywords:  Gene delivery; Immunotherapy; In vivo CAR-T; LNP; Lentiviral vector
    DOI:  https://doi.org/10.1016/j.jconrel.2026.115511
  18. J Transl Med. 2026 Jul 29. pii: 1346. [Epub ahead of print]24(1):
       BACKGROUND: Chimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment landscape for hematological malignancies, yet their large-scale manufacturing still faces significant technical, economic, and regulatory constraints. Microfluidic-mediated mechanical poration (MMP) has emerged as a promising non-viral strategy for intracellular delivery in cell engineering, offering high-throughput operation, reduced reagent consumption, and the possibility of preserving cell viability compared with conventional physical delivery methods.
    MAIN BODY: This review provides a structured assessment of the main MMP modalities, including constriction-based squeezing, volume exchange convective transfection (VECT), vortex shedding, spiral/viscoelastic hydroporation, and droplet mechanoporation, highlighting how device geometry, flow regime, and deformation mechanism influence delivery efficiency and cell integrity. Across the studies analyzed, reported delivery efficiencies frequently range from 60% to >95%, with cell viabilities commonly above 80-90% and processing capacities reaching from approximately 1 × 106 to 2.5 × 108 cells/min, depending on the device design, cargo, cell type, and operating conditions. Compared with viral vectors, MMP avoids complex vector production and may reduce biosafety and manufacturing burdens, while compared with electroporation, it may offer advantages in continuous-flow processing, cytotoxicity reduction, and cell recovery.
    CONCLUSIONS: Microfluidic-mediated mechanical poration shows strong potential as a next-generation intracellular delivery strategy for CAR-T cell manufacturing, combining efficiency, scalability, and reduced cytotoxicity. However, the current evidence remains uneven: many studies still rely on model cell lines or surrogate cargos, and direct validation in primary human T cells using CAR-encoding mRNA, DNA, or CRISPR-Cas9 components remains limited. Further optimization, regulatory alignment, and GMP-compatible integration are required to translate MMP from high-performing laboratory prototypes into reliable components of next-generation CAR-T cell manufacturing workflows.
    Keywords:  CAR-T cell; Fluid dynamics; Hydroporation; Microfabrication; Transfection
    DOI:  https://doi.org/10.1186/s12967-026-08388-4
  19. Biomolecules. 2026 Oct 08. pii: 1465. [Epub ahead of print]16(10):
      Viral infections remain a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in patients with delayed immune reconstitution or prolonged immunosuppression. Although antiviral drugs have substantially reduced the incidence of viral disease, their use is limited by toxicity, resistance, and the inability to restore long-term antiviral immunity. Adoptive transfer of virus-specific T cells represents a targeted immunotherapeutic strategy to re-establish pathogen-specific immune responses while minimizing the risk of graft-versus-host disease (GvHD). This review focuses on the development and clinical application of adoptive virus-specific T cell therapy after allogeneic HSCT, with particular emphasis on cytomegalovirus (CMV). We summarize the evolution of adoptive antiviral T cell therapy, compare current manufacturing and selection strategies, and critically review available clinical evidence regarding efficacy, persistence, safety, and alloreactivity. In addition to CMV-directed products, we discuss approaches targeting Epstein-Barr virus (EBV), adenovirus (AdV), and other clinically relevant pathogens in the context of multipathogen-specific T cell products and third-party donor approaches. We further address current knowledge on immune monitoring, factors influencing antiviral immune reconstitution, as well as practical challenges that still limit broader clinical use. Finally, we discuss emerging strategies to improve product standardization, availability, and integration of adoptive T cell therapy with modern antiviral prophylaxis and graft-engineering approaches.
    Keywords:  cellular therapies; cytomegalovirus; hematopoietic stem cell transplantation; immunocompromised host; viral infection
    DOI:  https://doi.org/10.3390/biom16101465
  20. J Cancer Res Clin Oncol. 2026 Oct 23. pii: 202. [Epub ahead of print]152(10):
      Chimeric antigen receptor-natural killer (CAR-NK) cells combine innate cytotoxicity with antigen-directed killing and promise as an immunotherapy with lower cytokine toxicity than CAR-T approaches. However, clinical translation is limited by challenges in transduction, persistence, tumor infiltration, and the immunosuppressive tumor microenvironment (TME). We performed a comprehensive literature review of recent preclinical and early-phase clinical studies, engineering strategies (CAR design, transduction technologies, gene-editing), manufacturing and expansion protocols, and trial outcomes in this review. We noted a reference to the advantages of CAR-NK, like multimodal killing (CAR-dependent and innate pathways), potential for allogeneic "off-the-shelf" use, and favorable early safety profiles. However, NK-specific obstacles persist: lower viral transduction efficiencies, short in vivo persistence, poor infiltration into solid tumors, and TME-mediated suppression (TGF-β, adenosine, metabolic stress). Engineering countermeasures such as IL-15 expression, checkpoint receptor knockout, chemokine receptor co-expression (e.g., CXCR1/4), DAP10/DAP12-based signaling domains, and non-viral delivery (transposons/CRISPR) have shown preclinical promise. CAR-NK therapy has developed from concept to a clinically actionable treatment line for hematologic malignancies and shows emerging potential in solid tumors when combined with TME-modulating strategies. This review provides robust evidence about CAR-NK therapies in hematological and solid tumors, with a great emphasis on the challenges they encounter, strategies, and innovative approaches to overcome these challenges, and forward-looking perspectives to improve future therapeutic CAR-NK designs and clinical outcomes.
    Keywords:  CAR-NK; Cancer; Cellular therapy; Chimeric antigen receptor; Immunotherapy; Natural killer cells
    DOI:  https://doi.org/10.1007/s00432-026-06635-1
  21. Cancers (Basel). 2026 Oct 09. pii: 3254. [Epub ahead of print]18(20):
      Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory hematological malignancies, producing deep and durable responses in B-cell acute lymphoblastic leukemia, aggressive B-cell non-Hodgkin lymphomas, and multiple myeloma. Nevertheless, antigen escape, limited in vivo persistence, T-cell exhaustion, and toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) limit broader application. This review synthesizes the mechanistic basis and clinical evidence for the currently approved CAR T-cell products and examines engineering strategies designed to overcome these barriers, including "armored" CAR T cells, multitargeted and logic-gated constructs, and modular or universal platforms intended to extend this approach beyond CD19-positive disease. Combination strategies with immune checkpoint inhibitors, radiotherapy, and other immunotherapies are discussed, together with emerging biomarkers of response and toxicity. Continued optimization of CAR design, toxicity management, and manufacturing scalability will be essential for CAR T-cell therapy to become a foundational pillar of precision oncology.
    Keywords:  chimeric antigen receptor (CAR) T-cell therapy; hematological malignancies; immune checkpoint inhibitors; multiplexed antigen targeting; next-generation immunotherapy
    DOI:  https://doi.org/10.3390/cancers18203254
  22. Genes (Basel). 2026 Oct 13. pii: 1272. [Epub ahead of print]17(10):
       BACKGROUND: CAR T-cell therapy has transformed the treatment of hematologic malignancies, although conventional autologous αβ CAR-T products remain limited by complex manufacturing, variable persistence, and relapse risk. γδT cells provide a promising donor source for next-generation off-the-shelf CAR-T therapies due to their MHC-independent tumor recognition, potent cytotoxicity, and minimal risk of graft-versus-host disease; however, the determinants of treatment durability following allogeneic CAR-γδT-cell therapy remain poorly defined. NETs have recently emerged as key immunoregulatory components of the TME, where excessive NET formation sustains inflammation, reshapes immune-stromal interactions, and impairs lymphocyte function, yet their impact on CAR-T-cell fate is largely unknown.
    METHODS: In this study, we performed longitudinal single-cell transcriptomic profiling of patients treated with allogeneic CAR-γδT cells and integrated ligand-receptor inference, pathway enrichment, and transcriptional regulatory analyses.
    RESULTS: We identified a 69-gene NET-associated transcriptional signature in the neutrophil population captured in PBMC samples. The NET-associated transcriptional score increased longitudinally in the single patient who subsequently relapsed, whereas longitudinal patterns varied across individual patients. Exploratory analyses identified associations between NET-associated transcriptional activity and T-cell functional programs, including an inverse association with proliferation. NicheNet, pathway enrichment, and SCENIC analyses highlighted candidate inflammatory and regulatory programs involving IL-1-related signaling, adhesion pathways, SMAD3 regulon activity, and E2F-related proliferative programs. Analysis of an independent cohort provided supportive evidence for related inflammatory transcriptional patterns, although differences in therapeutic platform and cellular composition limited direct validation.
    DISCUSSION: Together, these findings suggest that NET-associated inflammatory states may be linked to peripheral immune remodeling and altered circulating T-cell functional states during CAR-γδT-cell therapy. Larger longitudinal cohorts, more comprehensive clinical annotation, and orthogonal measurements of NET formation are needed to establish the clinical and mechanistic significance of these associations.
    Keywords:  CAR–γδT; NETs; immunotherapy; lymphoma; neutrophils
    DOI:  https://doi.org/10.3390/genes17101272
  23. Oncology (Williston Park). 2026 Sep 09. 40(7):
      Experts at the 2025 ICE-T Symposium reviewed CAR T-cell therapy, bispecific antibodies, and gene therapy across myeloma, lymphoma, autoimmune disease, and solid tumors, emphasizing safety and access.
    DOI:  https://doi.org/10.46883/2026.25921245
  24. J Nanobiotechnology. 2026 Aug 01. pii: 998. [Epub ahead of print]24(1):
      Neoantigen vaccines have become an important direction in cancer immunotherapy because mutation-derived tumor antigens can induce highly specific T-cell responses while minimizing immune tolerance associated with tumor-associated antigens. However, their therapeutic performance remains limited by several delivery-related barriers, including rapid antigen degradation, insufficient lymphatic trafficking, weak dendritic-cell activation, and inefficient cross-presentation. Nanotechnology provides flexible strategies to overcome these limitations. This review first summarizes the major delivery mechanisms by which nanocarriers enhance neoantigen presentation and T-cell priming, followed by recent preclinical and clinical advances in neoantigen nanovaccine platforms. Beyond these advances, we highlight the heterogeneity of clinical outcomes across different vaccine platforms and emphasize that vaccine-induced immunogenicity does not always translate into objective clinical benefit. We then analyze major translational bottlenecks, including prolonged neoantigen identification, tumor heterogeneity and neoantigen loss, formulation variability, manufacturing scalability, quality control, and tumor microenvironment-mediated immune resistance. Emerging strategies, including artificial intelligence-assisted neoantigen prioritization, broad-spectrum antigen induction, immunogenicity enhancement, RNA and nanocarrier platform optimization, rational combination therapy, clinically relevant model validation, and biomarker-driven patient stratification, are further discussed. Finally, we propose that future development should integrate rational nanocarrier design with patient stratification, tumor microenvironment modulation, large-scale multicenter clinical validation, standardized manufacturing, and robust potency evaluation. This review aims to provide a translational perspective for the rational development of next-generation neoantigen nanovaccines with improved efficacy, safety, and clinical feasibility.
    Keywords:  Antigen delivery; Cancer immunotherapy; Clinical translation; Nanovaccine; Neoantigen
    DOI:  https://doi.org/10.1186/s12951-026-04868-3
  25. Curr Protoc. 2026 Nov;pii: e70503. [Epub ahead of print]6(11):
      Glioblastoma (GBM) is the most lethal primary brain tumor in adults, and despite intensive research efforts, effective therapeutic breakthroughs remain elusive. Consequently, the standard of care has remained largely unchanged for nearly 30 years, underscoring the need for robust preclinical models to evaluate experimental therapies. One particularly promising approach is chimeric antigen receptor (CAR) T cell therapy, which has demonstrated remarkable success in several hematologic malignancies but has not yet achieved comparable efficacy in solid tumors. This article describes the generation of orthotopic GBM xenografts in NSG mice, including anesthesia, surgical procedures, and postoperative care, followed by locoregional delivery of human CAR T cells into the lateral ventricle and subsequent assessment of therapeutic efficacy. Together, these protocols provide a reliable platform for evaluating GBM-directed CAR T cell therapies in both basic and translational research. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Intracranial tumor implantation Basic Protocol 2: Intraventricular CAR T cell administration Support Protocol 1: Bioluminescence imaging of xenografts Support Protocol 2: Endpoint analysis of residual tumor burden by flow cytometry.
    Keywords:  CAR T cells; bioluminescence; flow cytometry; glioblastoma; stereotactic surgery
    DOI:  https://doi.org/10.1002/cpz1.70503
  26. Biomedicines. 2026 Sep 23. pii: 2147. [Epub ahead of print]14(10):
      Background: Ovarian cancer treatment is frequently complicated by postoperative recurrence associated with metastatic dissemination and acquired chemotherapy resistance, highlighting the need for new therapeutic approaches. Messenger RNA (mRNA)-based chimeric antigen receptor (CAR) T-cell therapy is a promising strategy for solid tumors because it enables transient CAR expression and may shorten the manufacturing process compared with lentiviral approaches. Given the potential relevance of rapid, transient CAR expression to locoregional or adjuvant applications, we evaluated an mRNA-based CAR-T cell approach targeting cancer antigen 125 (CA125) in vitro. Methods: CAR-T cells were generated from either activated or nonactivated ("resting") lymphocytes obtained from healthy donors using mRNA electroporation. Their activity against target tumor cells was assessed by impedance-based real-time cell analysis (RTCA) using the xCELLigence platform. Results: We compared two mRNA CAR-T cell manufacturing strategies: "fast" CAR-T cells generated using a 3-day activation-based workflow and "ultra-fast" CAR-T cells generated from nonactivated T cells and functionally evaluated within 24 h after electroporation. "Fast" CAR-T cells exhibited strong in vitro activity, including at an effector-to-target ratio of 1:4, representing a high target-cell burden. "Ultra-fast" CAR-T cells were also functional but showed lower activity, with an observable effect requiring an effector-to-target ratio of at least 2.5:1. Conclusions: These findings support the feasibility of rapid mRNA-engineered anti-CA125 CAR-T cell manufacturing using either activated or nonactivated T cells. The two approaches differ in functional activity and may therefore be suitable for different manufacturing workflows and intended applications.
    Keywords:  CAR T; immunotherapy; mRNA; ovarian cancer; solid tumor
    DOI:  https://doi.org/10.3390/biomedicines14102147
  27. Mol Ther Nucleic Acids. 2026 Dec 08. 37(4): 103117
      Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of B cell malignancies, and extending this success to other cancers remains an urgent clinical objective. CRISPR activation (CRISPRa) is a gene nomination platform with the potential to direct next-generation cell product development, but genome-wide surveys using this technology in primary T cells have been limited by prohibitive cell requirements and short-lived activity. Here, we describe a CAR-restricted T cell expansion platform generating yields of CRISPRa-CAR T cells far exceeding those required for genome-scale screening (∼109). CRISPRa activity is sustained by incorporating divergent, duplicate elongation factor 1α core/human T cell leukemia virus hybrid promoters and by delivering guide RNAs late by lentiviral transduction to avoid losing perturbations that compromise early T cell activation or expansion. Manufactured CRISPRa-CAR T cells maintain potent on-target gene overexpression (>85% target+) across varied cell subsets, including those associated with T cell exhaustion, and over extended culture periods. When applied to survival-based genome-wide screens, CRISPRa-CAR T cell pools nominate endogenous genes that enhance CAR T cell persistence across varied cytokine levels in the presence of tumor (e.g., IRF4, GFI1, and GSE1). In a proof-of-concept study, we find that the survival effect of GSE1 can be preserved using a clinically relevant transgene overexpression strategy. More broadly, this screening framework establishes a foundation for systematic identification and downstream validation of genes that enhance cellular therapies.
    Keywords:  CAR T cells; CRISPRa; MT: Delivery Strategies; T cell persistence; adoptive cell therapy; cancer immunotherapy; functional genomics; gain-of-function screening; genome-wide CRISPR screen; synthetic immunology; tumor microenvironment
    DOI:  https://doi.org/10.1016/j.omtn.2026.103117
  28. Front Immunol. 2026 ;17 1929923
      Regulatory T cells (Tregs) are essential for enforcing immune tolerance and homeostasis, but they comprise several distinct populations that differ in developmental origin, activation state, tissue adaptation, and functional specialization. These differences shape where Tregs reside, which immune responses they suppress, and how stable their lineage remains over time. This heterogeneity matters increasingly as immunology and therapeutics move from bulk Treg measurements toward subset- and context-specific interpretations. Treg-directed strategies now range from expanding Tregs to treat autoimmune disease to inhibiting tumor Tregs to enhance tumor immunity. In this review, we use three questions (who heterogeneous Tregs are, where they come from, and where they go) to organize recent advances that explain how Tregs are generated and maintained, how they traffic and adapt across tissues, and how their states shift across physiology and diseases. We also delineate Treg heterogeneity with a particular focus on contrasts between naïve Tregs (nTregs) and effector Tregs (eTregs), including defining markers and key biological features. We aim to provide a practical framework for interpreting human Treg datasets and for selectively using distinct Treg subsets in experimental design and therapeutic development.
    Keywords:  Treg heterogeneity; adoptive cell therapy; effector Treg; immune tolerance; naïve Treg; regulatory T cells
    DOI:  https://doi.org/10.3389/fimmu.2026.1929923
  29. Crit Rev Oncog. 2026 ;31(2): 47-53
      The seminal studies of the late Prof. Zelig Eshhar, the creator of "T-bodies," ushered in a new era of targeted cellular immunotherapy. As T-bodies came to be known as chimeric antigen receptors (CARs), the molecular requirements of these fusion proteins evolved, as did the technology enabling their expression in T cells. CAR T cells are fast becoming a mainstay therapy for hematological cancers such as multiple myeloma, and they are expanding into the field of solid cancer therapy. Nonetheless, one key barrier to their applicability is the limited number of tumor-specific targets that have been validated. An alternate approach which has until recently been almost totally bypassed is the use of peptide libraries to screen for and discover ligands capable of guiding the engineered T cells to novel cancer cell-restricted receptors. Peptides as targeting moieties have many advantages. This review summarizes the current state-of-the-art in the discovery and application of peptide-guided CAR-T cells in cancer immunotherapy.
    DOI:  https://doi.org/10.1615/CritRevOncog.2026066487
  30. Int J Pharm. 2026 Oct 24. pii: S0378-5173(26)01029-X. [Epub ahead of print]706 127580
      Chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy has emerged as a promising immunotherapeutic strategy for cancer treatment, offering advantages over CAR-T cells such as a lower risk of cytokine release syndrome and graft-versus-host disease and the potential for off-the-shelf manufacturing. Viral vectors have long served as effective tools for CAR-NK engineering, but their dependence on complex manufacturing procedures, considerable production costs, and the potential risks associated with genomic integration has encouraged increasing interest in non-viral alternatives. Recent advances in genetic engineering technologies have facilitated the development of CAR-NK platforms, particularly through non-viral delivery approaches including electroporation, transposon systems and lipid nanoparticles, while CRISPR-based tools enable targeted genome editing. Meanwhile, an increasing number of clinical trials have begun to evaluate the safety and therapeutic potential of CAR-NK cells in both hematological malignancies and solid tumors. However, challenges such as limited NK-cell persistence, antigen heterogeneity, and the immunosuppressive tumor microenvironment remain. In this review, we summarize recent progress in non-viral CAR-NK engineering strategies, analyze the current landscape of preclinical and clinical trials, and discuss key challenges and future directions for advancing CAR-NK therapy. Collectively, these advances suggest that non-viral engineering technologies may serve as an important technological foundation for next-generation CAR-NK therapies, enabling more flexible ex vivo manufacturing and potentially supporting the future development of in vivo CAR-NK generation strategies for solid tumors.
    DOI:  https://doi.org/10.1016/j.ijpharm.2026.127580
  31. Indian J Radiol Imaging. 2026 Oct;36(4): 621-634
      Oncology digital twins are patient-specific computational models that are built by combining electronic health records, multiomics genomic data, and diagnostic imaging to simulate individual tumor biology and predict multiple treatment-related outcomes. Conceptually originated from aerospace engineering, it has matured clinically through convergent advances in radiomics, mechanistic tumor modeling, pharmacokinetic- pharmacodynamic systems, federated machine learning, and, most recently, large language model (LLM)-based clinical interfaces and agentic artificial intelligence (AI). For a practicing radiologist, digital twins offer a transformative role: imaging-derived quantitative features serve as the primary data, positioning diagnostic imaging at the center of these personalized oncology workflows. Key clinical applications especially in oncology span from chemotherapy response prediction, immunotherapy patient selection, personalized radiation planning, tumor progression modeling, and treatment toxicity forecasting. Several of these applications are achievable with current technology without any significant infrastructure investment. Substantial challenges include imaging data standards, absence of prospective validation, algorithmic bias in underrepresented populations, and regulatory uncertainty for continuously self-updating AI. This narrative review provides radiologists with a balanced, comprehensive overview of digital twin architecture, advanced enabling technologies, current clinical evidence, a practical roadmap for implementation, and a candid appraisal of barriers to adoption.
    Keywords:  digital twin; multimodal data fusion; personalized therapy; precision oncology; radiology
    DOI:  https://doi.org/10.1055/s-0046-1827804
  32. Crit Rev Oncol Hematol. 2026 Oct 27. pii: S1040-8428(26)00563-9. [Epub ahead of print] 105676
      Bispecific immune cell engagers are among the most promising modalities in cancer immunotherapy, having made a significant impact on the treatment of hematological malignancy. However, their translation to solid tumors has remained challenging, leaving a critical gap for most cancer patients. A central obstacle is the lack of a mechanistic framework that integrates the complex biology of solid tumors with clinical outcomes, preventing a coherent interpretation of trial failures and impeding the development of more effective strategies. This review addresses that gap. We have reviewed clinical data from diverse engager formats recruiting T cells, NK cells, γδ T cells and monocytes across both successful and discontinued programs, showing how target selection, antigen accessibility, effector choice and molecular engineering collectively determine efficacy, half-life, tolerability and durability of response. We thereby construct a clinically grounded framework for designing next-generation engagers.
    Keywords:  Bispecific Immune cell engager; antibody engineering; cancer immunotherapy; clinical trial outcomes; solid tumor; translational oncology
    DOI:  https://doi.org/10.1016/j.critrevonc.2026.105676
  33. Cell Insight. 2026 Dec;5(6): 100377
      Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable and durable responses in hematologic malignancies, but its efficacy in solid tumors remains limited and frequently transient. In this Review, we propose that interacting tumor barriers divert persistently engaged CAR-T cells toward dysfunctional and exhausted states. Defective trafficking, antigen heterogeneity, incomplete tumor clearance, metabolic deprivation, stromal exclusion, immunosuppressive cellular networks, inhibitory cytokines, chronic CAR signaling, and manufacturing-imprinted stress collectively shape the stimulation history and functional trajectory of CAR T-cells. Mechanistically, these pressures converge on NFAT-AP-1 imbalance, TOX/TOX2 and NR4A activation, mitochondrial dysfunction, and exhaustion-associated epigenetic remodeling. This process creates a clinically relevant continuum between TCF1-positive progenitor-exhausted cells that retain self-renewal and checkpoint-responsive proliferative potential, and terminally exhausted cells with limited regenerative capacity. Building on this failure-pressure-fate model, we propose a mechanism-informed therapy framework that relates dominant failure mechanisms and residual CAR T-cell plasticity to potential intervention priorities. This approach may help match combination strategies to the dominant tumor pressure and CAR T-cell state, including stromal remodeling, metabolic engineering, cytokine armoring, checkpoint modulation, epigenetic intervention, and remanufacturing. Overall, this Review provides a fate-based framework for designing next-generation CAR T-cell therapies capable of achieving durable control in solid tumors.
    Keywords:  CAR T-cell fate; CAR T-cell therapy; Solid tumor; T cell exhaustion; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.cellin.2026.100377
  34. Rinsho Ketsueki. 2026 ;67(9): 1366-1375
      Advances in chemotherapy have improved survival rates for acute lymphoblastic leukemia (ALL); however, further intensification of chemotherapy is no longer feasible, and novel therapies are required for relapsed or refractory disease. Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has demonstrated high remission rates and significantly transformed treatment strategies, although toxicity, relapse, and limited indications remain ongoing challenges. This review summarizes the efficacy and safety of tisagenlecleucel, which is approved in Japan, as well as CAR-T products available overseas. It also discusses prognostic factors (such as pre-infusion tumor burden, prior treatment history, and genetic abnormalities), post-infusion biomarkers, and post-treatment management. Furthermore, it outlines the current status and challenges of novel therapies under development, including dual-targeting CAR-T cells and CAR-T therapy for T-cell ALL.
    Keywords:  B-cell acute lymphoblastic leukemia; CD19 CAR-T cell; Post-infusion biomarker; Prognostic factors
    DOI:  https://doi.org/10.11406/rinketsu.67.1366
  35. Pharmaceutics. 2026 Oct 16. pii: 1316. [Epub ahead of print]18(10):
      Genome engineering has transformed cell therapy, but clinical implementation remains largely confined to ex vivo workflows followed by adoptive cell transfer. These approaches require costly manufacturing, often rely on viral vectors, and carry risks associated with unwanted genomic alterations. Recent advances in lipid nanoparticles (LNPs) enable genome-editing components to be delivered directly to specific cell populations in vivo, eliminating the need for ex vivo manufacturing. Several RNA-based genome-editing approaches have entered clinical trials. Nevertheless, current in vivo approaches remain largely limited to gene disruption or small sequence modifications. Conventional integration of large payloads generally requires DNA donors, which can be immunogenic, have limited nuclear access, and pose substantial LNP formulation challenges. When expression of therapeutic proteins such as chimeric antigen receptors (CARs) is required, LNP-based approaches predominantly deliver mRNA, leading to transient expression, whereas many applications require durable expression through stable genomic integration. Retrotransposons offer a solution because they have naturally evolved to reverse-transcribe RNA templates directly into chromosomal DNA. Engineered retrotransposon-derived platforms can integrate multi-kilobase payloads from RNA without an exogenous DNA donor. These platforms combine durable expression with RNA-only delivery, but clinical translation requires safe permanent integration, copy-number control, efficient delivery of all required components, and sufficient activity in disease-relevant primary cells. In this review, we describe the classes of non-LTR retrotransposons; examine the design principles underlying their adaptation as genome-editing tools; and compare emerging platforms derived from R2, LINE-1, Vingi, and RTE elements. These systems support integration strategies ranging from naturally evolved insertion profiles, such as site-specific insertion into ribosomal DNA (rDNA) or dispersed genome-wide integration, to fully programmable insertion. Several retrotransposon-based platforms have demonstrated multi-kilobase payload insertion, functional engineering of primary human T cells, and in vivo activity in mouse or non-human primate models, demonstrating their clinical promise. We also discuss key translational challenges. With continued optimization, retrotransposon-based platforms have the potential to bridge the gap between transient RNA delivery and durable gene writing, establishing a versatile foundation for the next generation of in vivo genetic medicines.
    Keywords:  CAR-T cells; L2-2; LINE-1; R2; RTE-1; Vingi-1; gene integration; genome editing; in vivo genome engineering; lipid nanoparticles; non-LTR retrotransposons; retrotransposons
    DOI:  https://doi.org/10.3390/pharmaceutics18101316
  36. Front Immunol. 2026 ;17 1979396
      Asthma is a heterogeneous chronic airway disease, and some patients remain inadequately controlled despite optimized inhaled therapy and targeted biologics. Chimeric antigen receptor (CAR)-engineered cells are being explored as a programmable approach to depleting pathogenic immune cells, regulating local inflammation, and potentially achieving durable disease control. This narrative review evaluates the biological rationale, therapeutic targets, cellular platforms, engineering strategies, evidence levels, and translational challenges of CAR-engineered cell therapy for asthma. Available studies have directed CAR-based recognition toward IL-5Rα-positive eosinophils and their progenitors, membrane IgE-positive cells, FcϵRIα-positive effector cells, disease-relevant allergens, and tissue-associated antigens. However, no asthma-directed CAR product has undergone clinical validation. Clinical translation will depend on overcoming the limited disease specificity imposed by target heterogeneity and expression on normal immune populations, while ensuring that engineered cells remain sufficiently controllable in terms of persistence, reversibility, and toxicity. These biological challenges must also be balanced against the practical demands of conditioning, manufacturing, cost, and appropriate patient selection. Translation should prioritize human target validation, clinically relevant chronic disease models, controllable CAR designs, and carefully selected patients with severe, biologic-refractory type 2-high asthma. CAR-engineered cells represent a promising experimental platform rather than an established alternative to current asthma therapy.
    Keywords:  CAR-NK; CAR-NKT; CAR-T/CCAR-T; CAR-Treg; asthma; chimeric antigen receptor; type 2 inflammation
    DOI:  https://doi.org/10.3389/fimmu.2026.1979396
  37. Hum Gene Ther. 2026 Oct 27. 10430342261502532
    Preclinical Cancer Drug Development Network “preCDD” sponsored by the German Cancer Aid
      Over the past two decades, oncology has achieved remarkable progress, mainly due to the broad implementation of novel generation immunotherapies. Despite the majority of cancer cases nowadays being curable, a significant portion of cancers remains incurable, highlighting the ongoing gap between biological discoveries and clinically applicable therapies. Marked unmet needs for novel drugs are remaining; at the same time, drug development is nearly exclusively performed by the pharmaceutical industry. For academic drug discovery, a major hurdle in the drug development process is the "valley of death"-the transition from preclinical to clinical stages, where promising academic findings often fail to benefit patients due to a lack of infrastructure, expertise, and funding. The preclinical Cancer Drug Development network (preCDD), which is funded through the Deutsche Krebshilfe (German Cancer Aid), is an ambitious and structurally innovative academic response to this challenge. By bringing together three distinct academic research consortia-TACTIC, THUNDER, and CAR FACTORY-under one comprehensive network, preCDD creates an integrated, nationally distributed platform that encompasses small molecule development, next-generation protein engineering, and advanced cellular immunotherapy. This commentary explores the scientific rationale, organizational structure, and translational potential of the preCDD initiative as a compelling model for how publicly funded academic drug discovery can be systematically organized to bridge the gap between discovery science and clinical application. The initiative also makes expertise, technology, and platforms available to other academic groups to more broadly advance the development of new therapies in an academic setting.
    Keywords:  CAR; CAR factory; TACTIC; drug development; thunder
    DOI:  https://doi.org/10.1177/10430342261502532
  38. Front Immunol. 2026 ;17 1879293
      Chemokine-receptor axes are traditionally viewed as leukocyte trafficking cues, but increasing evidence indicates that they also function as spatial and functional organizers of immune-tumor communication. In the tumor microenvironment, chemokine gradients determine which immune-cell subsets are recruited, where they are positioned, and whether they acquire antitumor or suppressive states. This review summarizes experimentally validated chemokine-receptor axes that shape spatial niches, immune exclusion, and therapy resistance in cancer. The CXCL12-CXCR4 axis serves as a prototype of stromal immune exclusion, particularly in pancreatic cancer, where CXCR4 blockade can improve immune accessibility but may require myeloid-directed combinations. CXCR2 ligand axes, including CXCL5-CXCR2 and IL-8/CXCR2 signaling, promote neutrophil-rich suppressive niches, CD8+ T-cell dysfunction, PD-L1 induction, and resistance to immune checkpoint blockade or chemotherapy. The CCL20-CCR6 axis recruits regulatory T cells and contributes to metastatic immune suppression, whereas CCL5-CCR5 signaling organizes perivascular macrophage niches and supports adaptive therapy resistance. CCL2-associated macrophage circuits further link monocyte recruitment, TAM polarization, and immunotherapy responsiveness. We discuss how single-cell and spatial technologies can validate these circuits and guide biomarker-driven therapies. Rather than targeting isolated ligand-receptor pairs, future strategies should reprogram chemokine-controlled immune ecosystems to overcome immune exclusion and treatment resistance.
    Keywords:  chemokine receptors; chemokines; immune exclusion; spatial niches; therapy resistance; tumor microenvironment
    DOI:  https://doi.org/10.3389/fimmu.2026.1879293
  39. Cancers (Basel). 2026 Oct 21. pii: 3400. [Epub ahead of print]18(20):
      Peripheral T-cell lymphomas (PTCL) comprise a biologically diverse and clinically aggressive family of mature T/NK-cell neoplasms, for which outcomes remain poor in the majority of patients treated with conventional anthracycline-based frontline regimens. Contemporary classifications (WHO-HAEM5 and ICC) increasingly incorporate immunophenotypic and molecular information, underscoring that "PTCL-NOS" is not a single disease but rather a diagnostic umbrella that includes biologically distinct entities and molecular subgroups. Among these are the TBX21- and GATA3-driven PTCL-NOS subsets, the latter associated with inferior survival and a distinctive cytokine/microenvironmental program. These advances, many of which were shaped by long-standing contributions from the Bologna group, support a rational shift from empiric chemotherapy toward mechanism-based and immune-based interventions. CAR-engineered cellular therapies have revolutionized the care of B-cell malignancies, yet translation to PTCL has been delayed by lineage-specific barriers: (i) fratricide during manufacturing when targeting shared T-cell antigens (e.g., CD5, CD7), (ii) the risk of profound and prolonged T-cell aplasia (a markedly less "replaceable" toxicity than B-cell aplasia), and (iii) product contamination by malignant T-cells in autologous platforms. Recent progress in genome editing (CRISPR/Cas9 and base editing), intracellular antigen "blocking" strategies, and alternative effectors (allogeneic "universal" CAR-T, CAR-NK, and iPSC-derived platforms) has begun to address these obstacles at the manufacturing level, while their downstream clinical consequences (e.g., prolonged cytopenias, infectious risk and delayed immune reconstitution) remain incompletely resolved. Early-phase clinical trials now demonstrate clinically meaningful responses for select targets, particularly CD7, CD5, TRBC1 and CD30, for the pan-T targets. However, the strongest efficacy data remain largely derived from T-cell lymphoblastic malignancies (T-ALL/T-LBL), whereas evidence in mature PTCL remains limited and at an earlier stage, with target-specific differences in safety, immune reconstitution and relapse patterns. This review synthesizes the biological rationale for antigen selection in PTCL, the emerging clinical evidence for leading CAR targets, and the engineering strategies most likely to improve the therapeutic index. It also proposes an integrated hematology perspective on how CAR-based therapies might be positioned relative to transplant and evolving targeted agents in relapsed/refractory PTCL.
    Keywords:  CAR-NK; CAR-T; CD30; CD5; CD7; PTCL-NOS; TRBC1; fratricide; genome editing; peripheral T-cell lymphoma; tumor microenvironment
    DOI:  https://doi.org/10.3390/cancers18203400
  40. Cancers (Basel). 2026 Oct 18. pii: 3370. [Epub ahead of print]18(20):
       BACKGROUND/OBJECTIVES: CD19-directed chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory large B-cell lymphoma (r/r LBCL), yet primary resistance and relapse remain common. We evaluated how recent clinical and translational evidence refines established resistance frameworks and which knowledge gaps prevent the relative contribution of individual mechanisms from being determined.
    METHODS: We conducted a structured narrative review of 14 selected clinical and translational studies addressing tumor-, product-, host-, and microenvironment-related dimensions of treatment failure, synthesized across four interpretive domains and compared with nine previous reviews.
    RESULTS: Durable benefit was associated with favorable tumor and immune transcriptional programs and greater CAR T-cell fitness, expansion, or persistence. Treatment failure was associated with tumor-intrinsic resistance programs, exhausted T-cell states, systemic inflammatory signals, and suppressive tumor-microenvironment features, including PD-L1-expressing macrophages. Antigen escape remained relevant, but incomplete serial CD19 assessment precluded conclusions about its relative contribution. Comparison with earlier reviews showed continuity rather than replacement, with LBCL-focused evidence adding biological resolution.
    CONCLUSIONS: Resistance and relapse after CD19 CAR T-cell therapy in LBCL are multifactorial. Prospective longitudinal studies integrating tumor tissue, apheresis and manufactured products, peripheral blood, and matched relapse samples are needed to validate predictive biomarkers and guide rational treatment strategies.
    Keywords:  T-cell exhaustion; antigen escape; cellular fitness; immune evasion; predictive biomarkers; spatial transcriptomics; tumor microenvironment
    DOI:  https://doi.org/10.3390/cancers18203370
  41. Cancer Treat Rev. 2026 Oct 29. pii: S0305-7372(26)00148-9. [Epub ahead of print] 103234
      Small cell lung cancer (SCLC) remains one of the most lethal thoracic malignancies, characterized by rapid progression, early metastasis, and limited durable responses to conventional therapy. Delta-like ligand 3 (DLL3), a Notch pathway inhibitory ligand aberrantly overexpressed on the surface of approximately 70-85% of SCLC tumor cells but largely absent from normal adult tissue, has emerged as a compelling and therapeutically actionable target. Early efforts to exploit DLL3 through the antibody-drug conjugate (ADC) rovalpituzumab tesirine (Rova-T) yielded important mechanistic insights despite failing to demonstrate survival benefit in phase III trials and have since catalyzed a new generation of more refined DLL3-directed strategies. This review critically examines the evolving portfolio of DLL3-targeted therapies across three principal modalities: T-cell engagers, ADCs, and chimeric antigen receptor T-cell (CAR-T) therapies. In parallel, we examine emerging non-DLL3 therapeutic strategies reshaping the broader SCLC landscape. We additionally discuss the translational science underpinning DLL3 as a biomarker, including the emerging roles of circulating tumor cell-based liquid biopsy and DLL3-directed immunoPET-CT imaging in patient selection and treatment monitoring.
    Keywords:  ADC; BiTE; CAR-T; DLL3; Notch signaling pathway; Small cell lung cancer
    DOI:  https://doi.org/10.1016/j.ctrv.2026.103234
  42. Brief Bioinform. 2026 Sep 01. pii: bbag586. [Epub ahead of print]27(5):
      Bulk T cell receptor (TCR) sequencing enables scalable immune repertoire profiling but does not measure the transcriptional states required to infer T cell functional programs. Paired single-cell RNA/TCR sequencing offers a single-cell functional prior by jointly observing TCR identity and transcriptomic states. However, transferring this prior to bulk repertoires is challenging: sparse and noisy single-cell profiles can distort the functional reference, and the probabilistic relationship between TCR identity and transcriptome-inferred functional state makes direct cell-level alignment unstable, potentially biasing repertoire-level functional composition estimation. We present scMAC, a single-cell-guided framework for functional context completion that infers TCR functional representations reflecting transcriptome-derived T-cell states. scMAC builds a denoised functional reference by integrating multi-scale expression modeling with gene-semantic priors derived from large language model encodings of gene and protein descriptions, improving gene-level functional coherence. It then learns a prototype-guided TCR-to-function mapping that combines paired cell-level latent alignment with functional prototype regularization, enabling robust repertoire-level functional composition estimation. Across real single-cell and paired RNA/TCR datasets, scMAC outperformed existing single-cell representation methods in fine-grained cell-state representation, gene functional consistency, expression recovery, and disease-relevant pathway analysis, achieving an adjusted Rand index of 0.656 on a colorectal cancer dataset with 83 cell subtypes. For repertoire-level functional composition estimation, scMAC closely matched single-cell-derived functional proportions, with an R2 of 0.979 and a Bray-Curtis distance of 0.075. These results support scMAC as a practical route for transferring single-cell-derived functional knowledge to bulk TCR repertoire analysis beyond clonotype identity and clonal abundance. scMAC is publicly available at https://github.com/Bioinformatics7181/scMAC.
    Keywords:  bulk TCR sequencing; functional context completion; immune repertoire analysis; large language models; prototype learning; single-cell RNA/TCR sequencing
    DOI:  https://doi.org/10.1093/bib/bbag586
  43. Crit Rev Oncog. 2026 ;31(2): 23-33
      Professor Zelig Eshhar, a colleague, collaborator, and dear friend, is known worldwide as the visionary who laid the foundations for chimeric antigen receptor (CAR)-T cell therapy, a breakthrough that transformed cancer immunotherapy. Long before this revolutionary achievement, however, Zelig profoundly influenced research at the Weizmann Institute of Science by introducing the then state-of-the-art hybridoma technology for the generation of monoclonal antibodies (mAbs), which he brought directly from the oven of Nobel laureates Georges Köhler and César Milstein. Through his expertise and the dedication of his legendary team, Tova Waks, his indispensable partner for 55 years, Orith Gigi-Leitner, and Sara Barak, this technology rapidly became an invaluable resource for investigators throughout the Institute. My collaboration with Zelig during the 1980s led to the generation of monoclonal antibodies against a series of biologically important proteins, including interferons, other cytokines, their soluble receptors, the unique IL-18 Binding Protein (IL-18BP), and, years later, glutamate oxaloacetate transaminase 1 (GOT1). These antibodies proved to be remarkably versatile research tools, suitable for neutralization, affinity chromatography, immunoassays, flow cytometry, immunoblotting, and numerous other applications. Most importantly, they enabled the affinity purification of in-house corresponding recombinant cytokines. The antibodies proved far more than analytical reagents. They became indispensable tools for both basic research and translational medicine. Together, these unique reagents formed the foundation of a ligand-affinity strategy that led to the discovery of previously unknown cytokine receptors and binding proteins. Those include the type I interferon receptor, the second TNF receptor (TBPII), and the unexpected IL-18 Binding Protein. These discoveries not only advanced our understanding of cytokine biology but also paved the way for therapeutics such as RebifŴ, EnbrelŴ, RemicadeŴ and Tadekinig alfaTM, used in the treatment of autoimmune, inflammatory, and genetic diseases, such as multiple sclerosis, rheumatoid arthritis and Crohn's disease. While our scientific paths diverged in 1989, Zelig's toward the revolutionary concept of chimeric antigen receptors and mine toward cytokine receptors and binding proteins, they ultimately converged again as TNF and IL-18BP antagonists found applications in enhancement of CAR-T therapy and in management of potential inflammatory complications associated with this therapy. This chapter stands as a testament to Zelig's vision in introducing and advancing monoclonal antibody technology at the Weizmann Institute.
    DOI:  https://doi.org/10.1615/CritRevOncog.2026066174
  44. Mol Ther Adv. 2026 Dec 10. 34(4): 201856
      Lentiviral vector (LVV)-mediated chimeric antigen receptor (CAR)-T cell therapy has transformed the landscape for blood cancer treatment through genetic modification of patients' T cells. Yet, the complexity of the manufacturing process makes this therapy inaccessible for many patients. Systemic intravenous delivery of LVV is an attractive prospect not only for CAR-T therapeutics but also extends the potential benefit to inherited monogenic diseases. However, immunogenicity to LVV is a major hurdle to safe and efficacious gene delivery in vivo. Here, we categorize the immune responses into three main challenges: displacement of LVV from its intended target cells by components of the blood, inefficient transduction of target cells due to evolutionarily conserved viral detection and restriction, and clearance of the transduced cell population by the adaptive immune system. We review the progress toward in vivo delivery and the many approaches explored to circumvent immune barriers, from direct engineering of the LVV itself to pharmacological intervention. We report that while many approaches demonstrate improved efficacy, they often tackle only one aspect in isolation in a selected animal model. Therefore, we recommend researchers adopt a more holistic approach, testing a cocktail of strategies in a model that best recapitulates gene delivery to patients.
    Keywords:  gene therapy; immune evasion; immunogenicity; lentiviral vectors; systemic delivery
    DOI:  https://doi.org/10.1016/j.omta.2026.201856
  45. Mol Ther Oncol. 2026 Dec 17. 34(4): 201354
      Chimeric antigen receptor-macrophages (CAR-Ms) represent a promising platform for solid tumors, but barriers limiting durable responses remain incompletely defined. Antigen shedding may be a key barrier because, unlike T cells, macrophages require sustained antigen engagement for effective phagocytosis. However, whether shed antigen directly impairs CAR-M function has not been established. Using mesothelin (MSLN) as a model target, we generated CAR-Ms targeting either an N-terminal epitope (SS1) or a membrane-proximal, non-shed epitope (15B6). Shed MSLN markedly impaired the phagocytic and cytotoxic activity of SS1 CAR-Ms, establishing antigen shedding as a direct functional barrier. In contrast, 15B6 CAR-Ms remained largely resistant and showed stronger antigen-specific activity across multiple MSLN+ tumor cells, demonstrating that rational epitope selection can overcome this barrier. In immunocompetent, MSLN-tolerant transgenic mouse models of colorectal and pancreatic cancer, 15B6 CAR-Ms demonstrated superior anti-tumor activity. In colorectal tumor-bearing mice, a single infusion of 15B6 CAR-Ms significantly prolonged survival, with 35% achieving complete tumor regression. Rechallenge of cured mice with MSLN- tumor cells resulted in complete tumor rejection, suggesting the development of durable systemic anti-tumor immunity. Together, these findings identify antigen shedding as a critical barrier and support epitope selection as an important design strategy for CAR-M therapies targeting shed tumor antigens.
    Keywords:  CAR-macrophage; antigen shedding; colorectal cancer; immunotherapy; pancreatic cancer
    DOI:  https://doi.org/10.1016/j.omton.2026.201354
  46. Cells. 2026 Oct 19. pii: 1902. [Epub ahead of print]15(20):
      Allogeneic chimeric antigen receptor (CAR)-based cell products and induced pluripotent stem cell (iPSC)-derived regenerative grafts increasingly use multilayer immune engineering. Current strategies are strongest against direct human leukocyte antigen (HLA)-dependent recognition but incompletely address natural killer (NK)-cell counter-pressure, priming by recipient antigen-presenting cells, humoral and complement-mediated injury, inflammatory remodeling, blood- and tissue-interface damage, and terminal cell killing. Poxvirus research has characterized diverse immunomodulatory mechanisms relevant to these barriers. We review poxviral control of interferon signaling, antigen processing and presentation, T-cell activation, NK-cell surveillance, cytokine and chemokine networks, complement, inflammatory signaling, and regulated cell death, integrating viral mechanisms with human perturbation, cell-engineering, and transplantation evidence. A qualitative Tier 1-3 framework distinguishes mechanisms close to current cell-therapy practice from those requiring greater product-specific validation or control. The resulting design rules favor graded antigen-presentation control with paired NK validation, local or transient inflammatory buffering, interface-restricted complement protection, and survival enhancement only when independent eliminability is preserved. Selected poxviral proteins can act autonomously outside productive infection, but direct viral-protein expression remains a selective rather than default option. We propose a conditional defense-in-depth framework in which modules are added only when a residual barrier is demonstrated in the final therapeutic product.
    Keywords:  CAR-NK cells; CAR-T cells; NK-cell surveillance; allogeneic cell therapy; antigen presentation; complement regulation; hypoimmune engineering; iPSC-derived cell products; interferon signaling; poxvirus immune evasion
    DOI:  https://doi.org/10.3390/cells15201902
  47. Rinsho Ketsueki. 2026 ;67(9): 1336-1343
      Hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe disorders, including refractory hematologic malignancies and inborn errors of immunity. The increasing use of HLA-haploidentical transplantation and intensive immunosuppressive strategies has resulted in a growing population of patients at high risk for post-transplant viral infections. Viral infections after HCT are often refractory to currently available antiviral agents and remain a major cause of transplant-related morbidity and mortality. Effective viral control requires the reconstitution of virus-specific immunity; however, donor-derived antiviral immune responses often take considerable time to develop after transplantation. Against this background, virus-specific T-cell (VST) therapy has emerged as a promising immunotherapeutic approach. Recent advances have led to the development of third-party (TP), off-the-shelf VST products and multi-virus-specific T-cell (MVST) products capable of targeting multiple viruses simultaneously. Cryopreserved VST products enable rapid therapeutic intervention for patients with refractory viral infections. Furthermore, the approval of tabelecleucel for Epstein-Barr virus-associated post-transplant lymphoproliferative disease in Europe marks an important milestone in the clinical translation of VST therapy. This review summarizes the history, manufacturing strategies, clinical development, and key clinical trial results of VST therapy, with a particular focus on TP-VST and TP-MVST platforms and their development in Japan.
    Keywords:  Adenovirus; Adoptive immunotherapy; Hematopoietic cell transplantation; Virus-specific T cell
    DOI:  https://doi.org/10.11406/rinketsu.67.1336
  48. Transplant Cell Ther. 2026 Oct 24. pii: S2666-6367(26)00845-6. [Epub ahead of print]
       BACKGROUND: Virus-specific T-cell (VST) therapy is used in the management of viral complications after allogeneic HSCT. Current VST products are polyclonal and heterogeneous. This limits standardization, potency assessment, and precise product characterization. T-cell receptor (TCR)-based engineering may allow antiviral specificity to be captured from donor-derived immunity and redirected into a more defined cellular therapy candidate.
    OBJECTIVE(S): To identify a functional cytomegalovirus (CMV)-reactive TCR from a donor-derived VST product administered to a patient, generate and characterize a defined anti-CMV TCR-T cell candidate, and assess TRAC knockout as a strategy to support endogenous TCR removal in future allogeneic applications.
    STUDY DESIGN: A trivalent donor-derived VST product generated against adenovirus, BK polyomavirus, and CMV was administered under compassionate use to a pediatric haploidentical HSCT recipient with post-transplant viremia. Serial post-infusion blood samples were used to assess changes in the peripheral T-cell receptor repertoire over time. The clinical VST product was re-stimulated with the human leukocyte antigen (HLA)-A*02:01-restricted CMV pp65 495-503 epitope. Antigen-responsive CD8⁺4-1BB⁺ cultures were used for functional TCR recovery. The selected CMV-reactive TCR was reconstructed with murine constant regions, cloned into an MSGV1 gamma-retroviral vector, and introduced into primary human T cells. Engineered cells were assessed for introduced TCR expression, antigen-specific activation, interferon-gamma (IFNγ) secretion, HLA-A*02:01-restricted recognition, endogenous TCR expression over time, and generation of a TRAC-disrupted TCR-T cell population.
    RESULTS: Peripheral TCR repertoire analysis after sequential VST infusions showed temporal changes in dominant circulating TCRβ clonotypes, with annotation based on overlap with antigen-responsive CD4⁺ and CD8⁺ reference datasets generated from the clinical VST product. Functional re-stimulation of the VST product with pp65 495-503 enriched antigen-responsive CD8⁺4-1BB⁺ cells. From these cultures, a CMV-reactive TCR was recovered and advanced based on reproducible peptide-specific activity. Following reconstruction and retroviral transfer, the selected TCR mediated pp65 495-503-specific activation and IFNγ secretion in primary T cells. Stimulation with pp65 495-503 induced 35.82% CD3⁺OX40⁺4-1BB⁺ cells and approximately 9.8 × 10³ pg/mL IFNγ, while responses to non-cognate adenoviral Hexon stimulation remained low. The engineered anti-CMV TCR-T cells showed stronger IFNγ responses to pp65 495-503 than the parental VST product. Irrelevant TCR controls remained near baseline. Endogenous TCR expression decreased early after TCR transduction alone but recovered by approximately day 14 and persisted through day 35. Following CRISPR/Cas9-mediated TRAC knockout, approximately 70% of cells were within the intended mTCR⁺hTCR⁻ population before sorting, and this population was enriched by flow sorting for downstream characterization.
    CONCLUSION(S): This study demonstrates a clinically grounded workflow for deriving a defined antiviral TCR-T cell candidate from a donor-derived VST product. A functional CMV-reactive TCR was recovered from the clinical VST product and redirected into primary T cells while preserving pp65-specific activity. The recovery of endogenous TCR expression after transduction alone indicates that early downmodulation is not sufficient for durable removal of the native TCR. Incorporating TRAC knockout therefore provides a strategy to generate a more defined engineered T-cell population for future antiviral cellular therapy development.
    Keywords:  T-cell receptor engineering; TCR-T cells; TRAC knockout; antiviral cellular therapy; cytomegalovirus; hematopoietic stem cell transplantation; virus-specific T cells
    DOI:  https://doi.org/10.1016/j.jtct.2026.10.034
  49. Hematol Oncol Stem Cell Ther. 2026 Oct 01. 19(2): e0019
       INTRODUCTION: Despite growing evidence supporting the benefits of rehabilitation across the treatment continuum, the extent to which physiotherapy (PT) is represented at professional hematopoietic cell transplant (HCT) and chimeric antigen receptor therapy (CAR-T) conferences remains unclear. This study therefore aimed to evaluate the visibility of PT content at major international HCT and CAR-T conferences over the past 5 years.
    METHODS: A scoping review of publicly available conference programs and proceedings was conducted for major HCT and CAR-T conferences held between 2021 and 2025 across Europe, the United Kingdom, the United States, and the Middle East (n = 28 conferences). Programs were screened for PT-related content presented as dedicated sessions or within multidisciplinary, supportive care, nursing, or survivorship programs. For contextual comparison, oncology PT conferences (n = 4) held during the same period were also reviewed.
    RESULTS: Dedicated PT or rehabilitation scientific tracks were uncommon across the HCT and CAR-T conferences reviewed. PT/rehabilitation related content, where identified, was typically embedded within broader nursing, supportive care, or survivorship sessions. The International Society of Pediatric Oncology demonstrated the most consistent inclusion of rehabilitation-related presentations, while limited abstracts were identified within selected HCT conferences despite the absence of dedicated PT tracks. In contrast, oncology PT conferences consistently included dedicated rehabilitation-focused scientific sessions.
    CONCLUSION: This review identified limited visibility of PT and rehabilitation within publicly available HCT and CAR-T conference programs despite the growing evidence supporting rehabilitation across the cellular therapy continuum. These findings highlight an opportunity to strengthen multidisciplinary engagement and improve the visibility of rehabilitation science within future conference programs. However, conference programs represent only one component of knowledge translation and cannot determine whether observed representation reflects abstract submission patterns, conference programming decisions, or the broader rehabilitation research landscape. Future studies evaluating abstract submission and acceptance data are warranted.
    Keywords:  CAR-T; Physiotherapy; conferences; hematopoietic cell transplantation; musculoskeletal; rehabilitation
    DOI:  https://doi.org/10.4103/hemoncstem.hemoncstem-D-26-00019
  50. J Exp Clin Cancer Res. 2026 Jul 31. pii: 224. [Epub ahead of print]45(1):
       BACKGROUND: Cancer immunotherapy, including immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapy, and bispecific antibodies, has transformed the treatment of advanced malignancies, yet primary and acquired resistance remain major barriers to durable benefit. Across these therapies, resistance reflects the failure of one or more of three shared requirements for effective antitumor immunity: tumor immune visibility, lost through defective antigen presentation and interferon signaling; immune access to tumor nests, restricted by stromal and vascular barriers; and effector cell function, undermined by suppressive myeloid and regulatory populations, metabolic restriction, and loss of tertiary lymphoid structures.
    MAIN BODY: In this review, we argue that resistance to targeted therapies, endocrine therapies, and PARP inhibitors should not be treated as a problem separate from immunotherapy resistance. Rather, these resistant states often converge on the same three axes that govern immunotherapy resistance (immune visibility, access, and effector function), yielding a unified framework across therapeutic classes. Using canonical immunotherapy resistance as a reference model, we examine how osimertinib resistance, androgen receptor (AR)-pathway-resistant states, and BRCA reversion-mediated PARP inhibitor resistance may remodel these same immune-evasion axes. Targeted therapy resistance provides the most complete case, with epithelial-mesenchymal transition, PD-L1 upregulation, STING suppression, and immune exclusion extending across all three axes. AR pathway reactivation shows plausible links to immune remodeling through direct MHC-I repression and myeloid reprogramming, although the clinical evidence base remains less mature. BRCA reversion illustrates a mechanistically suggestive dual-valence state in which restored DNA repair may diminish innate immune sensing while also generating computationally predicted junctional neopeptides whose immunogenicity remains to be validated.
    CONCLUSIONS: By reframing resistance as a new immune state that converges on the same three immune-evasion axes rather than a terminal event, this review shifts attention from why a therapy failed to which immune-evasion axis now predominates and how it might be countered. This perspective supports mechanism-matched combination therapy, adaptive molecular monitoring, and cautious exploitation of vulnerabilities generated by the resistant state itself. As an organizing model rather than a claim of uniform causality, the framework now requires prospective validation.
    Keywords:  Cancer therapy resistance; Combination therapy; Immune evasion; Immunotherapy; PARP inhibitor resistance; Targeted therapy; Tumor microenvironment
    DOI:  https://doi.org/10.1186/s13046-026-03798-0
  51. Drug Des Devel Ther. 2026 ;20 638795
      T cell engagers (TCEs) have emerged as transformative agents in multiple myeloma, driving a paradigm shift through advances in molecular engineering and clinical application. This review examines these developments across structural design and clinical optimization. Structurally, the field has evolved from IgG-like formats enabling subcutaneous administration toward multi-specific architectures designed to circumvent antigen escape and enhance tumor selectivity. Clinically, strategies have been refined by early TCE integration to leverage preserved immune fitness, step-up dosing to mitigate cytokine release syndrome, and combinations with gamma-secretase inhibitors or immunomodulatory drugs to overcome resistance. However, key limitations persist: antigen loss and lineage plasticity; on-target/off-tumor depletion of normal plasma cells with hypogammaglobulinemia and infection; T-cell exhaustion under continuous exposure; and the absence of predictive biomarkers for response, toxicity, and sequencing. Future efforts should prioritize conditional or logic-gated formats that decouple potency from systemic exposure, target rotation to preempt escape, biomarker-driven selection with minimal residual disease-guided duration, and home-based subcutaneous delivery. Integrating bioengineering innovation with optimized clinical protocols while confronting these constraints will be essential for TCEs to deliver durable remissions and advance the prospect of a functional cure for MM.
    Keywords:  T cell engagers; bispecific antibodies; combination therapies; immunotherapy; multiple myeloma; structural design; trispecific antibodies
    DOI:  https://doi.org/10.2147/DDDT.S638795
  52. EJHaem. 2026 Dec;7(6): e70437
       Introduction: Relapsed/refractory post-transplant lymphoproliferative disorder (PTLD) remains a challenging complication after solid organ transplantation (SOT), requiring complex balancing of immune-suppressive therapy (IST) and lymphoma-directed therapies.
    Methods: We report the case of a 40-year-old female kidney-pancreas transplant recipient with relapsing monomorphic PTLD treated with CD19-chimeric antigen receptor (CAR) T cells therapy (axicabtagene ciloleucel).
    Results: Tacrolimus discontinuation and immunosuppression with everolimus and corticosteroids permitted robust CAR T-cell expansion, complete lymphoma remission, and preservation of graft function. In vitro studies showed that tacrolimus inhibited CAR T-cell function, while everolimus preserved it, supporting the use of mTOR-based, calcineurin-inhibitor-free IST during CAR T-cell therapy in SOT recipients.
    Conclusion: mTOR-based, calcineurin inhibitor-free immunosuppression can preserve CAR T-cell function and enable effective therapy in SOT recipients with PTLD.
    Keywords:  calcineurin inhibitor; chimeric antigen receptor T‐cell (CAR‐T); everolimus; immunosuppression; post‐transplant lymphoproliferative disorder (PTLD); solid organ transplantation; tacrolimus
    DOI:  https://doi.org/10.1002/jha2.70437
  53. Cell Tissue Bank. 2026 Oct 30. pii: 61. [Epub ahead of print]27(4):
      Umbilical cord blood (UCB) stem cells and mesenchymal stromal cells from cord tissue (UC-MSCs) have served as the foundation for regenerative and cellular therapy research for over 30 years and are also the scientific basis for the global private cord blood banking industry; however, it is uncertain whether clinical evidence has kept pace with the therapeutic claims made. This structured narrative review characterizes how clinical translation for both UCB and UC-MSC evolved between 2015 and 2025, using clinical trial registers, regulatory decisions and systematic reviews/meta-analyses, and asks whether this pathway is consistent with value propositions used in private cord blood banking marketing. Although plateauing following the results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1101 trial, UCB transplantation remains clinically relevant through ex-vivo expansion (Omidubicel/Omisirge, approved by the U.S. Food and Drug Administration [FDA] in 2023 and 2025) and other cord-blood-derived products such as chimeric antigen receptor natural killer (CAR-NK) cells. Infusion of autologous UCB for neurological indications shows an acceptable safety profile but variable efficacy; a phase II autism study found no benefit on its primary endpoint. UC-MSC research has expanded significantly, with meta-analytic support now available for knee osteoarthritis and, from mixed-source MSC studies, autoimmune disease, and early-phase evidence for liver failure and diabetic nephropathy. The center of gravity of perinatal stem cell innovation has shifted from autologous transplantation toward manufactured, largely allogeneic therapeutics, which may alter the underlying assumptions regarding informed consent that guide private CBB practice, a claim this review does not itself test empirically.
    Keywords:  Cellular therapy; Cord blood banking; Mesenchymal stromal cells ; Regenerative medicine; Umbilical cord blood
    DOI:  https://doi.org/10.1007/s10561-026-10260-0
  54. Front Oncol. 2026 ;16 1980190
      Therapeutic mRNA vaccines are a clinically validated cancer immunotherapy platform using in vitro transcribed mRNA encoding tumor antigens to induce durable anti-tumor immunity. Advances in mRNA engineering, lipid nanoparticle (LNP) delivery, and immunomodulatory combinations have propelled this approach from preclinical models to randomized trials with survival benefit. This review systematically examines vaccine efficacy through an antigen-delivery-immunomodulation tripartite framework. We trace the evolution from shared tumor-associated antigens to personalized neoantigens identified by computational pipelines, discuss ionizable lipid chemistry and LNP formulation for controlled tissue tropism and transfection, and analyze the bidirectional crosstalk between vaccine components and innate immune sensing that shapes adaptive T cell responses. Clinical evidence across melanoma, pancreatic cancer, non-small cell lung cancer, and other solid tumors is critically evaluated, alongside combination strategies-checkpoint blockade, oncolytic virotherapy, and adoptive cell therapy to overcome TME resistance. Persistent challenges include optimal neoantigen selection, standardized immune monitoring, and predictive biomarkers. We conclude that future research should prioritize systematic optimization of the tripartite design through multi-antigen targeting, tissue-specific delivery engineering, and rational combination immunotherapy, aiming to establish mRNA cancer vaccines as a standard-of-care modality.
    Keywords:  cancer immunotherapy; combination therapy; innate immune; mRNA vaccine; personalized vaccine; tumor antigen
    DOI:  https://doi.org/10.3389/fonc.2026.1980190
  55. Methods Mol Biol. 2027 ;3089 591-601
      Expression of chimeric antigen receptors enables T cells to be redirected toward melanoma-associated antigens in an MHC-independent manner. Retroviral transduction can be used to introduce these receptor constructs into murine CD4⁺ and CD8⁺ T cells. Here, we outline the generation of retroviral supernatants and the activation, transduction, expansion, and selection of murine T cells expressing the chimeric-PD1 receptor. This protocol can be adapted for any murine chimeric antigen receptor construct.
    Keywords:  Chimeric antigen receptor; Immunotherapy; Melanoma; Mouse; Retroviral transduction; T cell
    DOI:  https://doi.org/10.1007/978-1-0716-5619-8_39
  56. Acta Pharm Sin B. 2026 Oct;16(10): 6360-6377
      Antibody‒cell conjugates (ACCs) represent a promising therapeutic strategy emerging in the biopharmaceutical industry to overcome the limitations of current immunotherapies. ACCs constitute a novel class of living drugs developed by anchoring functional antibodies onto the surface of living cells via specific linkers or conjugation methods. These carrier cells encompass both immune effector cells (such as Natural Killer cells, γδ T cells, and activated T cells) and non-immune cells (such as erythrocytes and platelets). Distinct from genetic engineering, ACCs directly modify the cell surface using chemical biology, enzymatic catalysis, or physical assembly, thereby endowing cells with precise tumor-targeting capabilities while preserving their intrinsic biological functions. This technology facilitates the scalable production of "off-the-shelf" therapeutics and has shown promising potential in treating both hematological malignancies and refractory solid tumors with a superior safety profile. This review systematically examines the current construction strategies and carrier cell selection for ACCs, covering both immune effector cells and non-immune carrier cells, and discusses the clinical progress, key challenges, and future directions.
    Keywords:  Allogeneic cell therapy; Antibody‒cell conjugates; Cancer immunotherapy; Carrier cells; Clinical progress; Construction strategies; Non-genetic engineering; Off-the-shelf
    DOI:  https://doi.org/10.1016/j.apsb.2026.07.034
  57. Epigenomes. 2026 Oct 05. pii: 64. [Epub ahead of print]10(4):
      Epitranscriptomic drug discovery has mostly targeted the catalytic "writers" (METTL3/METTL14) and "erasers" (FTO, ALKBH5) that deposit and remove N6-methyladenosine (m6A). That strategy just hit clinical validation: STC-15, a METTL3 inhibitor, has measurable anti-tumor activity from a first-in-human oncology trial, but the same structural features that made these enzymes attractive also limit them. Inhibition shifts m6A stoichiometry globally, while an m6A mark's functional impact depends almost entirely on cellular context. YTHDF family reader proteins offer another angle. Their low-complexity domains drive liquid-liquid phase separation (LLPS). m6A binding stimulates this condensation across YTHDF paralogs-a property that matters for therapeutic selectivity. We propose a Phase Transition Threshold model in which YTHDF2's condensation concentration decides whether synaptic mRNAs are degraded or maintained in translation-competent, FMRP-associated states. Recent evidence has established YTHDF2 synaptic localization, FMRP condensate formation in neurons, and functional antagonism between the two proteins. The central unresolved question is whether condensation in living cells is nucleation-driven rather than bulk-concentration-driven. If so, concentration-centered pharmacology misses the point. We present falsifiable predictions and a staged experimental program. A more fundamental risk is that YTHDF2-mediated decay may not require condensate formation at all. If that is the case, the therapeutic premise of this Perspective collapses.
    Keywords:  FMRP; YTHDF2; condensate pharmacology; epitranscriptomic drug discovery; liquid–liquid phase separation; m6A RNA methylation; synaptic plasticity
    DOI:  https://doi.org/10.3390/epigenomes10040064
  58. Front Neurol. 2026 ;17 1903348
       Objective: To synthesize current evidence into a neurologist-focused workflow for early recognition, bedside monitoring, diagnostic triage, mitigation, and therapy-specific surveillance of immune effector cell-associated neurotoxicity syndrome (ICANS).
    Methods: PubMed/MEDLINE, Scopus, Web of Science Core Collection, and Google Scholar were searched in English from inception through 25 March 2026. Of 201 records, 18 duplicates were removed, 183 were screened, 157 full texts were assessed, and 26 studies were included in a narrative synthesis. The selection process was reported using applicable PRISMA 2020 elements and the narrative presentation was evaluated using SANRA.
    Results: Evidence supports early neurologic co-management in selected high-risk patients, serial language- and attention-sensitive bedside assessment, and clinically triggered rather than routine electroencephalography. Pilot neurocognitive data suggest that subtle decline may precede deterioration on the Immune Effector Cell-Associated Encephalopathy (ICE) score. Bispecific-antibody programs generally show lower neurotoxicity burdens than many CAR T-cell platforms but create repeated risk windows around step-up dosing and outpatient transition. Delayed B-cell maturation antigen (BCMA)-associated movement and neurocognitive syndromes remain an important safety signal, although therapeutic evidence is largely observational or case based.
    Conclusion: The evidence supports documenting a baseline neurologic phenotype, performing serial bedside monitoring, deploying electroencephalography and neuroimaging when results may change management, and maintaining product-specific vigilance for delayed syndromes. Tiered pathways are needed for community and resource-limited settings.
    Keywords:  BCMA; CAR T-cell therapy; ICANS; bispecific antibodies; electroencephalography; neurocritical care; neurotoxicity; outpatient workflow
    DOI:  https://doi.org/10.3389/fneur.2026.1903348
  59. Crit Rev Oncol Hematol. 2026 Oct 27. pii: S1040-8428(26)00560-3. [Epub ahead of print] 105673
      T-cell receptor-mimic antibodies (TCRm-Abs) have enabled the specific targeting of peptide-major histocompatibility complexes (p-MHCs), thereby granting access to intracellular tumor antigens that are typically inaccessible to conventional antibody therapeutics. Nevertheless, the extremely low density of these complexes on the surface of tumor cells has remained the primary challenge for all TCRm-Ab-based platforms. This review provides a critical comparison of various molecular platforms-including TCRm-immunoconjugates (TCRm-ICs) and TCRm-bispecific T-cell engagers (TCRm BiTEs)-as well as cellular platforms, such as TCRm-chimeric antigen receptor (TCRm-CAR), antibody T-cell receptor (AbTCR), and Synthetic TCR and Antigen Receptor (STAR). It evaluates their design and optimization strategies to overcome low antigen density, mechanisms of action, translational potential, and current challenges. Immunoconjugates rely on payload potency and linker stability, engager molecules achieve serial killing through T cells, whereas cellular platforms-particularly STAR-attain antigen sensitivity comparable to that of native T-cell receptors by mimicking the TCRαβ architecture. Nonetheless, the durable clinical translation of these modalities remains limited. Based on these insights, we propose a context-driven selection framework that integrates molecular engineering, modulation of the tumor microenvironment, combination immunotherapy, and quantitative tumor characteristics to inform the preclinical development and rational selection of TCRm therapeutic platforms.
    Keywords:  Cancer immunotherapy; Cellular immunotherapy; Peptide–major histocompatibility complex (p-MHC); T-cell receptor-mimic antibodies (TCRm-Abs); TCRm therapeutic platforms; TCRm- immunoconjugates; TCRm-engagers
    DOI:  https://doi.org/10.1016/j.critrevonc.2026.105673
  60. Neoplasia. 2026 Oct 24. pii: S1476-5586(26)00117-X. [Epub ahead of print]83 101385
      Tumor heterogeneity remains a major bottleneck for effective cancer therapy because many determinants of target expression, biomarker performance, and treatment resistance are spatially organized within the tumor ecosystem. Bulk molecular profiling averages these signals across cell populations, whereas dissociation-based single-cell approaches disrupt the tissue architecture that shapes cell state, signaling, and drug access. Spatial multi-omics addresses these limitations by mapping transcriptomic, proteomic, metabolomic, and epigenomic features in situ, while AI enables integration of these modalities with histology, spatial coordinates, and clinical outcomes. Current evidence suggests that graph-based and neighborhood-aware models are most useful for spatial domain detection and niche mapping, whereas multimodal and histology-based models require stronger external validation before clinical deployment. In this review, we examine how spatial multi-omics and AI are redefining tumor heterogeneity as a translational variable in oncology. We focus on target discovery, patient stratification, and resistance biology. We also discuss major barriers to clinical translation, including platform bias, FFPE compatibility, assay cost, molecular coverage, segmentation and registration errors, limited benchmarking, domain shift, and the need for independent multicenter validation.
    Keywords:  Drug resistance; Machine learning; Precision oncology; Spatial multi-omics; Spatial transcriptomics; Tumor heterogeneity
    DOI:  https://doi.org/10.1016/j.neo.2026.101385
  61. Sci Adv. 2026 Oct 30. 12(44): eaeh9188
      Regulatory T cells (Treg cells) maintain immune tolerance, but how broadly acting epigenetic pathways are selectively used by Treg cells versus conventional T cells (Tconv cells) remains unclear. Here, we identify the COMPASS-trimethylation of histone H3 lysine 4 (H3K4me3) pathway, through its Wdr82 component, as a key epigenetic regulator that preferentially supports Treg cell development and function. Although Wdr82 deficiency broadly impairs T cell activation, T cell-specific deletion paradoxically causes progressive, microbiota-dependent intestinal inflammation and expansion of inflammatory Tconv cell programs. This pathology is prevented by microbiome depletion or transfer of wild-type Treg cells, indicating a primary defect in Treg cell-mediated tolerance. Mechanistically, Wdr82/COMPASS promotes Foxp3 induction, maintains H3K4me3 and chromatin accessibility at Treg cell-associated genes, and restrains effector programs within the Treg cell lineage. Foxp3 coordinates with COMPASS components in a T cell receptor/costimulation-dependent manner, linking antigen receptor signaling to chromatin regulation. Together, these findings reveal selective integration of a broadly active epigenetic pathway into the Foxp3-centered regulatory hierarchy that sustains Treg cell control of microbiota-driven intestinal inflammation.
    DOI:  https://doi.org/10.1126/sciadv.aeh9188
  62. Nat Commun. 2026 09 24. pii: 11086. [Epub ahead of print]17(1):
      T-cell receptor (TCR) recognition of antigenic peptides presented by human leukocyte antigen (HLA) molecules underpins adaptive immunity and T cell-based immunotherapy. However, the scarcity of complete interaction data and TCR cross-reactivity challenge robust prediction. Here, we present UpTCR, a unified progressive knowledge-transfer foundation model that learns from incomplete data to predict TCR-antigen-HLA binding. UpTCR progressively transfers knowledge from dimeric and trimeric interactions to tetrameric complexes and uses soft contrastive learning to mitigate false negatives. It outperforms existing methods in predicting TCR binding specificity and antigen-HLA binding affinity, particularly for neoantigens, and reveals pairwise residue-level interactions across the tetramer. UpTCR also transfers effectively to breast cancer cohorts with limited data. Prospective validation against melanoma antigen variants identifies eight immunogenic peptides that elicit T cell responses and one variant associated with immune escape. These findings establish UpTCR as a generalizable and interpretable tool for studying antigen recognition and advancing TCR-based immunotherapies.
    DOI:  https://doi.org/10.1038/s41467-026-78075-x
  63. Sci Transl Med. 2026 Oct 28. 18(873): eaed9994
      Diffuse midline glioma (DMG) is a lethal pediatric brain tumor with limited therapeutic options and a poor prognosis. The success of chimeric antigen receptor (CAR) T cell therapy requires both improving T cell tumor infiltration and persistence and reducing the risk of on-target/off-tumor toxicity. Here, we adapted and advanced a brain-restricted CAR T cell platform previously validated in glioblastoma to address the anatomical and biological challenges of DMG. We engineered a T cell circuit in which a brain-specific synthetic Notch (synNotch) receptor recognizing brevican (BCAN) induced CAR expression against EphA2 or IL-13Rα2 ("B-SYNC"), thereby restricting CAR expression to the central nervous system (CNS). In immunodeficient DMG models, a single infusion of intravenous (iv) or intracerebroventricular (icv) B-SYNC circuit T cells led to tumor infiltration, sustained persistence, antitumor activity, and extended survival. An alternative BCAN-primed CAR targeting B7-H3 or IL-13Rα2 ("B-SYNC-B/I") similarly improved therapeutic efficacy when delivered intravenously. However, icv administration triggered fatal neurotoxicity because of low-level B7-H3 expression in nontumor CNS regions, indicating that rapid CNS exposure via icv delivery can amplify off-tumor toxicity. In contrast, in an immunocompetent syngeneic DMG model, both iv and icv delivery of a murinized BCAN-gated B7-H3 CAR (mB-SYNC-B7-H3) achieved durable tumor clearance and resistance to rechallenge without any detectable neurotoxicity. Mechanistically, synNotch-primed CAR T cells exhibited reduced exhaustion, enhanced activation, and enrichment of naïve and stem cell memory-like subsets. These findings demonstrate that brain-sensing synNotch CAR T circuits represent a generalizable and translatable strategy for targeting multiple CNS malignancies, including DMG.
    DOI:  https://doi.org/10.1126/scitranslmed.aed9994
  64. Biomolecules. 2026 Oct 04. pii: 1448. [Epub ahead of print]16(10):
       BACKGROUND: Pediatric solid tumors respond poorly to T-cell-directed immunotherapy despite expressing developmentally restricted, cancer-testis, fusion-derived, and lineage-associated antigens, suggesting that therapeutic failure may reflect defective conversion of intracellular antigen expression into surface peptide-major histocompatibility complex class I (pMHC-I) display. This review examines the antigen-presentation bottleneck as a framework for tumor immune invisibility and therapeutic resistance.
    METHODS: We conducted a narrative mechanistic synthesis of pediatric and translational evidence on antigen repertoires, MHC-I and antigen-processing machinery dysfunction, mechanisms of presentation loss, therapeutic restoration, pMHC-directed immunotherapy, and MHC-independent bypass strategies.
    RESULTS: Antigen expression does not reliably predict natural presentation. Presentation failure may result from HLA loss, coordinated transcriptional repression, developmental and epigenetic states, altered trafficking, SUMOylation, and autophagy-mediated MHC-I degradation. Potentially reversible defects can be targeted through cytokine signaling, NF-κB/IRF1/NLRC5 reactivation, epigenetic or lineage reprogramming, and inhibition of post-translational MHC-I loss; irreversible defects favor MHC-independent surface targeting.
    CONCLUSIONS: Pediatric solid tumors may be antigen-invisible rather than antigen-poor. Therapeutic matching should assess antigen abundance, HLA integrity, antigen-processing competence, natural peptide presentation, quantitative pMHC density, and spatial and longitudinal heterogeneity, then restore presentation or deliberately bypass it. The framework distinguishes the presentation phenotype (quantitative pMHC insufficiency versus qualitative loss or functional absence of a required HLA/APM element) from the underlying mechanism (soft/potentially reversible versus hard/structural) because these dimensions have different biomarker and therapeutic implications.
    Keywords:  HLA; MHC class I; TCR-T therapy; antigen presentation; cancer-testis antigens; immune evasion; immunopeptidomics; pediatric solid tumors
    DOI:  https://doi.org/10.3390/biom16101448
  65. Transpl Immunol. 2026 Oct 24. pii: S0966-3274(26)00124-3. [Epub ahead of print]99 102466
      Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and emerging allogeneic T cell therapies offer curative potential for hematologic malignancies, but their benefits remain constrained by graft-versus-host disease (GvHD). Although multiple signaling pathways contribute to GvHD, their effects are determined by dynamic interactions among immune cell subsets, tissue compartments, and disease stages rather than by isolated pathway activation. Here, we provide a network centered synthesis of major GvHD signaling pathways, including JAK/STAT, BTK/ITK, PI3K/AKT/mTOR, NF-κB, NFAT, MAPK, and Notch, with emphasis on pathway crosstalk, feedback, cellular and tissue context, and the distinct yet overlapping biology of acute and chronic GvHD. We further examine how network connectivity and context dependent signaling influence therapeutic responses and the challenge of suppressing pathogenic alloimmunity while preserving beneficial graft-versus-leukemia (GvL) activity. This framework highlights GvHD as a dynamically interconnected signaling disorder and provides a context aware basis for interpreting pathway directed therapies according to cellular context, disease stage, and the level of clinical evidence supporting each therapeutic approach.
    Keywords:  Allogeneic hematopoietic stem cell transplantation; Graft-versus-host disease; Graft-versus-leukemia; Pathway crosstalk; Signaling pathways
    DOI:  https://doi.org/10.1016/j.trim.2026.102466
  66. Drug Dev Res. 2026 Nov;pii: e70400. [Epub ahead of print]87(7):
      The pharmaceutical sector is undergoing considerable transformation as a result of the integration of artificial intelligence (AI), automation, robotics, and advanced computing technologies. Traditional pharmaceutical discovery and development processes can be lengthy, costly, and associated with high failure rates, thereby necessitating more efficient approaches. Agentic artificial intelligence (Agentic AI) combines autonomous decision-making, goal-oriented reasoning, adaptive learning, and multi-step task execution. These capabilities may increase the autonomy and coordination of pharmaceutical research workflows. At the same time, self-driving or autonomous laboratories that utilize robotics, machine learning, laboratory automation, and real-time data analytics to conduct experiments with minimal or no human intervention have emerged as an alternative approach. Agentic AI can provide a higher-level orchestration layer for autonomous laboratories, while established approaches such as Bayesian optimization, active learning, machine learning, and robotic experimentation provide many of the underlying capabilities required for closed-loop experimentation. These technologies can be applied to drug discovery, lead optimization, formulation development, process optimization, and personalized medicine. Several challenges related to data quality, transparency, regulation, cybersecurity, ethical considerations, and infrastructure must be addressed before these systems can be widely adopted. In addition, current evidence is dominated by computational studies, research-scale proof-of-concept platforms, and early industrial implementations. Substantial uncertainty remains regarding their reproducibility, scalability, and effects on overall drug development timelines. Rather than representing an established replacement for conventional pharmaceutical research, the convergence of Agentic AI and autonomous laboratories should currently be regarded as an emerging systems-level architecture that builds upon established approaches such as Bayesian optimization, active learning, robotic experimentation, and closed-loop optimization. Its potential value lies in extending autonomy from individual computational or experimental tasks toward coordinated research workflows, although the extent of this added value remains to be established through prospective and end-to-end validation. Accordingly, fully autonomous pharmaceutical research should be regarded as a long-term research objective rather than an established technological capability, with its realization dependent on further advances in scientific reasoning, experimental validation, regulatory governance, cybersecurity, and human-AI collaboration.
    Keywords:  Agentic AI; artificial intelligence; autonomous laboratories; digital twins; drug development; drug discovery; pharmaceutical research; precision medicine; robotics; self‐driving laboratories
    DOI:  https://doi.org/10.1002/ddr.70400
  67. Clin Transl Oncol. 2026 Oct 25.
      Peripheral immune tolerance, essential for preventing autoimmunity, is increasingly co-opted by tumors to drive progression, metastatic dissemination, and immunotherapy resistance. Whereas central tolerance eliminates autoreactive clones, peripheral tolerance remains dynamically regulated by antigen persistence, cytokine gradients, metabolic cues, and stromal architecture, a plasticity that tumors exploit to build a multilayered immunosuppressive ecosystem. This narrative review synthesizes multi-omic, spatial, cellular, and molecular evidence, emphasizing 2021 to 2025 publications alongside foundational studies, to propose tumor-induced peripheral tolerance (TIPT) as a unifying framework for immune escape and treatment failure. TIPT emerges from coordinated suppression by tumor-resident regulatory T cells, myeloid-derived suppressor cells, regulatory B cells, M2-like macrophages, tolerogenic dendritic cells, and exhausted CD8? T cells, sustained by suppressive cytokine networks, metabolic deprivation, epigenetic fixation of dysfunctional states, and stromal-vascular exclusion barriers. Spatially organized tolerance niches are associated with immune evasion, metastatic seeding, and resistance to checkpoint blockade. Strategies targeting suppressive cell populations, metabolic pathways, chromatin regulators, and stromal barriers are in clinical development, but clinical benefit has been established for only a limited subset, and anti-TIGIT antibodies failed to meet primary endpoints in phase 3 lung cancer trials. Machine-learning models show promise for predicting tolerance states and guiding combination design, but prospective clinical validation is still needed. TIPT may represent an important, potentially actionable determinant of tumor evolution and immunotherapy response, and durable cancer control is likely to require combined strategies that dismantle this tolerance ecosystem.
    Keywords:  Cancer immunotherapy; Immune checkpoint resistance; Immune evasion; Myeloid-derived suppressor cells; Regulatory T cells; Spatial transcriptomics; Tumor microenvironment; Tumor-induced peripheral tolerance
    DOI:  https://doi.org/10.1007/s12094-026-04590-4
  68. Pharmaceutics. 2026 Sep 27. pii: 1227. [Epub ahead of print]18(10):
      Physiologically relevant tumour models are increasingly used in cancer research, drug development, and functional precision oncology, yet selection often remains platform-led rather than biology-led. This structured critical narrative review proposes an operational framework linking model selection, engineering, and validation to six interdependent domains: multicellular organization and heterogeneity, extracellular-matrix architecture and mechanics, stromal regulation, vascular and interstitial transport, immune regulation and communication, and metabolic regulation with biochemical gradients. The framework distinguishes mechanism-guided questions, in which a candidate causal mechanism can be prespecified, from discovery-oriented questions, in which the determinant is unknown and candidate functions are tested through nested or factorial configurations before a minimal sufficient explanatory model is defined. Required functions are classified as essential, context-modifying, non-essential, or uncertain, and preservation-oriented, reconstruction-oriented, and hybrid strategies are distinguished from the technological format used to implement them. For pharmaceutical applications, delivered exposure, matrix or device binding, tissue penetration, transport, dosing schedule, and recovery are treated as qualification variables when they can change apparent potency or response. The practical contribution is a traceable biology-to-decision record linking the decision and mechanism status to function selection, model configuration, qualification evidence, complexity-retention rules, and claim boundaries. Model qualification is separated from external association, prospective predictive validity, and clinical utility. Among the representative studies appraised, direct functional and configuration-specific pharmacological evidence was demonstrated more often than interlaboratory transfer, independently validated prospective prediction, or clinical utility. Physiological relevance should therefore be demonstrated through decision-critical function rather than inferred from platform complexity or component count. The proposed decision rules remain unvalidated prospectively and across laboratories.
    Keywords:  bioprinting; drug delivery; drug discovery; functional precision oncology; multicellular tumour models; patient-derived models; physiologically relevant tumour models; tumour microenvironment; tumour organoids; tumour-on-chip
    DOI:  https://doi.org/10.3390/pharmaceutics18101227
  69. Biochim Biophys Acta Rev Cancer. 2026 Oct 30. pii: S0304-419X(26)00213-1. [Epub ahead of print] 189741
      Cancer immunotherapy has changed cancer treatment, with neoantigen-based vaccines emerging as a promising strategy to induce tumor-specific immune responses while minimizing adverse effects on healthy tissues. Advances in next-generation sequencing, immunopeptidomics, artificial intelligence, and computational prediction have accelerated the identification of patient-specific neoantigens and enabled the development of personalized cancer vaccines. Despite encouraging safety profiles and robust induction of neoantigen-specific T-cell responses, clinical efficacy has remained inconsistent. Tumor evolution driven by genomic instability continuously reshapes the neoantigen landscape through intratumoral heterogeneity, immune-mediated selection, and antigen gain or loss, facilitating immune escape and limiting durable therapeutic responses. In addition, T-cell dysfunction and the immunosuppressive tumor microenvironment further compromise vaccine efficacy. In this review, we discuss the origin and diversity of tumor antigens, recent advances in neoantigen identification and vaccine development, and the biological mechanisms that constrain the clinical success of personalized cancer vaccines. We summarize evidence from clinical trials that highlights both the promise and the current limitations of neoantigen-based immunotherapy, and discuss the importance of incorporating tumor evolution into vaccine design. Finally, we present Variable Epitope Libraries (VELs), a vaccine strategy that uses immunogens based on combinatorial libraries of highly mutated epitope variants designed to broaden immune recognition, reduce immune escape, and improve the durability and effectiveness of cancer immunotherapy.
    Keywords:  Cancer vaccine; Immune escape; Neoantigens; Tumor evolution
    DOI:  https://doi.org/10.1016/j.bbcan.2026.189741
  70. JMIR AI. 2026 Oct 30. 5 e98653
       Unlabelled: AI models have enabled substantial advances in health care. Since the entry into force of the European Union (EU) AI Act in 2024, these systems have become subject to a common regulatory framework in the EU intended to harmonize AI governance across all member states. One of the act's distinctive features is that it accommodates existing economic, technological, and regulatory differences among European countries by leaving certain implementation responsibilities to national authorities. This is evident in regulatory sandboxes, supervised environments for developing, testing, and validating AI systems before deployment. In this viewpoint, we provide a policy-oriented analysis of health care regulatory sandboxes under the EU AI Act and propose recommendations for their design. These recommendations address the need to document model compression techniques that may affect the classification of large high-risk systems above the 1025 floating point operations per second threshold, incorporate explainability into AI systems from the design stage, identify and document biases in health care datasets, clarify the treatment of federated learning parameter updates under the General Data Protection Regulation, and strengthen the oversight of AI agents in clinical environments. The implementation timeline makes this discussion particularly timely given the approaching deadline of August 2, 2027, by which all member states must have established at least one national regulatory sandbox.
    Keywords:  AI; EU AI Act; European Union AI Act; artificial intelligence; deep learning; delivery of health care; federated learning; regulatory sandboxes
    DOI:  https://doi.org/10.2196/98653
  71. Oncology. 2026 Oct 24. 1
      Messenger RNA (mRNA)-based therapeutics have emerged as a programmable platform with expanding relevance to neuro-oncology, where intracranial disease control remains difficult to achieve. Recent successes in systemic oncology have renewed interest in applying these approaches to primary and metastatic brain tumors. We performed a narrative synthesis of clinical, translational, and mechanistic studies evaluating mRNA-guided therapeutic strategies in glioblastoma (GBM) and brain metastases (BrM). In GBM, clinical experience has been dominated by dendritic cell-mRNA vaccination, which consistently demonstrates feasibility and the ability to induce antigen-specific immune responses, but only limited and inconsistent intracranial efficacy. This discrepancy reflects multiple converging constraints, including profound intratumoral immune suppression, heterogeneous blood-brain and blood-tumor barrier permeability that limits effector access and delivery exposure, and treatment-related immunosuppression, particularly corticosteroid use. Emerging mRNA modalities, including delivery-targeted mRNA systems and mRNA-enabled immune programming strategies such as transient chimeric antigen receptor (CAR) expression or local immunomodulatory payload delivery, offer theoretical advantages in localization, controllability, and safety. However, their translation remains constrained by biodistribution limitations, intratumoral heterogeneity, and uncertainty regarding reliable intracranial exposure across infiltrative tumor compartments. In brain metastases (BrM), systemic mRNA vaccine strategies appear more transferable because they rely primarily on peripheral immune priming rather than direct intracranial payload delivery, aligning with tumor types that already demonstrate responsiveness to immune checkpoint blockade. Nevertheless, intracranial efficacy remains influenced by lesion-level heterogeneity, including variable blood-tumor barrier permeability, differences in immune microenvironment permissiveness across lesions, and discordant intracranial versus extracranial treatment responses. Collectively, these findings indicate that while mRNA platforms are biologically active and mechanistically versatile, durable intracranial benefit depends on matching therapeutic modality to disease-specific delivery, immune, and microenvironmental constraints. mRNA-based therapies are biologically active and feasible in neuro-oncology, but durable intracranial benefits will require disease-specific strategies that explicitly address CNS barriers. Progress will depend on mechanism-driven combinations, steroid-aware trial design, and endpoints that directly assess intracranial immune engagement.
    DOI:  https://doi.org/10.1159/ocl/aebag027
  72. Acta Pharm Sin B. 2026 Oct;16(10): 6507-6525
      Antibody-based therapies have gained significant traction in oncology, as evidenced by their prominent presence at international conferences such as American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO). Modalities including antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs), and T-cell engagers (TCEs) are increasingly recognized as pillars of precision medicine. Driven by advances in molecular engineering, antibody formats and mechanisms of action have evolved beyond conventional antigen blockade to encompass multimodal cytotoxicity and immune modulation. ADCs now leverage optimized linkers and payloads for targeted delivery and potent tumor cell killing. BsAbs simultaneously engage tumor and immune cell targets to enhance immune activation, while TCEs enable T cells to recognize intracellular antigens presented via MHC, overcoming the limitations of extracellular targeting. Emerging design strategies are increasingly tailored to target-specific features such as expression levels, internalization capacity, and cellular subtype. Innovations include non-internalizing ADCs for low-abundance targets and biased antibody architectures that preferentially activate CD8+ T cells. These developments are expanding the therapeutic landscape toward greater efficacy, safety, and personalization. This review outlines the global landscape of antibody drug development, highlighting a paradigm shift toward target-driven design principles that integrate structural innovation with functional precision.
    Keywords:  Antibody engineering; Antibody–drug conjugate (ADC); Bispecific antibody (BsAb); Cancer immunotherapy; Precision oncology; T-cell engager (TCE); Target-driven design; Undruggable targets
    DOI:  https://doi.org/10.1016/j.apsb.2026.06.028
  73. Semin Oncol. 2026 Oct 09. pii: S0093-7754(26)00112-0. [Epub ahead of print]53(6): 152567
       BACKGROUND: Platelets contribute to tumor progression and immune regulation, but the relationship between pretreatment platelet count and immune checkpoint blockade (ICB) outcomes across the clinical range remains unclear.
    METHODS: This study conducted a retrospective multicohort study of patients treated with ICB. In a Memorial Sloan Kettering pan-cancer cohort (n = 1,479), platelet count was modeled using penalized cubic splines and clinically defined strata, with 150-249 × 10⁹/L as the reference. Cox models adjusted for age, sex, prior chemotherapy, ICB class, tumor stage, cancer type, and tumor mutational burden. Findings were evaluated in a validation cohort (n = 717) and in non-small cell lung cancer (n = 666) and melanoma (n = 377) analyses. An exploratory pooled analysis (n = 2,196) compared mono-ICB with dual PD-1/PD-L1 plus CTLA-4 blockade across platelet strata.
    RESULTS: Platelet count showed a U-shaped association with overall survival. Relative to 150-249 × 10⁹/L, adjusted mortality hazards were higher at 49-124 × 10⁹/L (hazard ratio [HR], 1.83; p = 0.0001), 300-399 × 10⁹/L (HR, 1.56; p < 0.0001), and 400-977 × 10⁹/L (HR, 1.93; p < 0.0001). High counts were also associated with shorter progression-free survival (HR, 1.27 for 300-399 × 10⁹/L and 1.32 for 400-977 × 10⁹/L; both p = 0.003), whereas associations at low counts were weaker. Similar patterns were observed in the validation and cancer-specific cohorts. Dual ICB was associated with longer median overall survival than mono-ICB only in the 150-300 × 10⁹/L stratum (2.34 vs 1.42 years; p < 0.0001).
    CONCLUSIONS: Pretreatment platelet count is an inexpensive biomarker with a nonlinear association with ICB outcomes. Both low and high counts identify increased mortality risk, supporting flexible modeling rather than a single thrombocytosis threshold. The platelet-defined signal for dual ICB is hypothesis-generating and requires prospective validation before treatment selection.
    Keywords:  Immune checkpoint blockade; Immunotherapy; Overall survival; Pan-cancer analysis; Platelet count; Progression-free survival
    DOI:  https://doi.org/10.1016/j.seminoncol.2026.152567
  74. J Vis Exp. 2026 Oct 27.
      Foundation models are being investigated in gastroenterology because the specialty already generates multimodal data, including endoscopy videos, pathology slides, abdominal images, laboratory results, molecular profiles, and longitudinal clinical notes. This review examines where these models may be useful in emerging applications, where evidence remains limited, and what is required before wider clinical deployment. Large language models (LLMs) can support document organization, report generation, guideline retrieval, and patient communication, but fluent output can conceal errors. Endoscopic models are beginning to move beyond single-task polyp detection towards reusable visual pretraining across gastrointestinal sites and procedures. Pathology and radiology foundation models may assist with biomarker prediction, image segmentation, and tumor detection, although performance remains sensitive to staining, scanners, acquisition protocols, and case mix. The immediate goal is not to build a single model that covers the entire specialty. Rather, gastroenterology needs systems that are locally validated, auditable, privacy-aware, uncertainty-calibrated, and sufficiently focused to remain within clinical responsibility.
    DOI:  https://doi.org/10.3791/74137
  75. J Pers Med. 2026 Oct 03. pii: 517. [Epub ahead of print]16(10):
      Despite significant advances in understanding the biology of inflammatory bowel diseases (IBD), the underlying etiology is still unknown, and currently available treatment options are not curative. Furthermore, even after the advent of multiple targeted "advanced" therapies, approximately one-third of patients do not respond to treatment, and approximately half of patients lose response over time. As a result, there have been efforts made to seek alternative treatment options. In recent years, there have been major advances made in the field of cellular therapy, involving administration of living cells to patients. Notably, the area with the most evidence base to date has been stem cell therapy, with data generated for both mesenchymal and hematopoietic stem cells. More recently, there have also been emerging data exploring the use of chimeric antigen receptor T cells and regulatory T cells. As the landscape for cellular therapy expands in the coming years, an important next step will be to understand which patients may or may not benefit from these therapies and at what point these treatment options might be considered in the disease course of IBD.
    Keywords:  CAR-T cells; cellular therapy; haemopoietic stem cell; inflammatory bowel disease; mesenchymal stem cell; regulatory T cells; stem cell transplantation
    DOI:  https://doi.org/10.3390/jpm16100517